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ABSTRACT 
Background: Patients with type 2 diabetes (T2D) suffer stroke more often and have worse 
recovery. Moreover, hyperglycemic stroke patients treated with thrombolytic therapy have more 
intracranial bleedings. Insulin is the gold standard for treatment of hyperglycemia, but has a 
significant risk of hypoglycemia, especially if rapid normalization of glucose is the goal. 
Glucagon like peptide-1 based drugs, such as receptor agonists (GLP-1RA) and 
dipeptidylpeptidase-4 inhibitors (DPP-4i) that raise the endogenous GLP-1 levels are used to treat 
T2D. Interestingly these drugs have been shown to reduce stroke incidence; and, importantly for 
this thesis, to exert acute neuroprotective effects in animal models if given before a stroke.  
Aim: To determine if GLP-1RA and DPP-4i are neuroprotective in animal models when given 
after stroke and to identify some of the underlying mechanisms. Furthermore, the aim was to 
determine the GLP-1 levels in humans after stroke and their relationship to outcome. Finally, to 
test treating hyperglycemic stroke patients with GLP-1RA early after stroke: in the ambulance.  
Study 1: An experimental animal study determining the effect of giving the GLP-1RA exendin-4 
(Ex-4) after the onset of stroke. We did this in both young and healthy animals as well as aged 
and obese/diabetic animals. Experimental stroke was induced by middle cerebral artery occlusion 
(MCAO). The main finding was that exendin-4 is neuroprotective if given after MCAO, both in 
young and old animals. The effect was time-sensitive with effect at 1.5 and 3 h after MCAO, but 
lost at the 4.5 h time point.  
Study 2: An experimental animal study where we determined if DPP-4i treatment had 
neuroprotective properties when started after the onset of stroke. Additionally, we studied if the 
effect was dependent of the GLP-1 receptor by using a GLP-1R -/- knockout model mouse. The 
main finding was that DPP-4 inhibitors require chronic pre-treatment to be effective. 
Furthermore, we showed that the effect is not dependent on the GLP-1 receptor.  
Study 3: In rats with diabetes (GK-rats) or without (Wistars) we studied the impact of aging in 
diabetes on regulatory GABA-ergic interneurons (key cells involved in stroke recovery) and 
whether treatment with the GLP-1RA exendin-4 could revert the observed changes. Main 
findings: 1: The number of GABAeric neurons decreased in aged diabetic animals. 2: Treatment 
with Ex-4 had effect on the subpopulation of GABAeric neurons positive for calbindin.  
Study 4: We determined the endogenous GLP-1 levels in patients treated with thrombolytic 
therapy for ischemic stroke. A group of 59 patients underwent a OGTT at day 2-4 during the 
hospital stay. A repeat OGTT was performed 3 months later. At the three-month follow-up 
functional stroke outcome was measured with mRS. 27 healthy controls underwent one OGTT. 
The main findings were that the GLP-1 level was higher in stroke patients and remained 
unchanged 3 months later. The GLP-1 level was not associated with functional outcome.  
Study 5: A randomized clinical trial examining the feasibility of prehospital treatment with 
exenatide in hyperglycemic patients (8-15 mmol/L) with suspected stroke. Patients were followed 
for 24 h. 19 patients were randomized, 8 received exenatide. There was no evidence of a 
difference in the main outcome of glucose at 4 hours. No adverse events were reported.  
Conclusion: Both GLP-1RA and DPP-4i are neuroprotective against stroke. The effect is, 
however, time sensitive with the need for early initiation after stroke (GLP-1RA) or chronic pre-
stroke treatment (DPP-4i). Additionally, the effect of DPP-4i is GLP-1 receptor independent. The 
findings encourage the use of these drugs for the treatment of diabetes.   
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1 INTRODUCTION 
1.1 RELATIONSHIP BETWEEN DIABETES AND STROKE 
1.1.1 Prevalence and risk factor 
422 million people worldwide had diabetes in 2014, a prevalence of 8,5 % among the adult 
population (1), out of which 90-95% is type 2 diabetes (T2D) (2). The number of persons 
living with diabetes is also rapidly increasing, with the sharpest rise in low-income countries 
and the Eastern Mediterranean Region (1).  
Stroke is a vascular disease affecting the brain with sudden loss of neurological function due 
to neuron cell asphyxia and defined by the World Health Organization (WHO) as: “rapidly 
developing clinical signs of focal or global disturbance of cerebral function, lasting more than 
24 h or until death, with no apparent non-vascular cause” (3). This can be due to either a 
hemorrhage, or more commonly, approximately 85%, an occlusion in one of arteries 
supplying the brain tissue causing an ischemic stroke (4, 5). Stroke affects around 21 000 
persons every year in Sweden (6) and it is the second most common cause of mortality in the 
world (7). The estimated cost per year for stroke in Sweden is 12.3 billion SEK, or an average 
of 600 000 SEK per individual (8).  
Diabetes increases the risk for vascular disease complications such as ischemic heart disease 
and stroke (1, 5). Diabetes is one of the major risk factors for developing ischemic stroke, 
along with old age, high blood pressure, smoking and atrial fibrillation (5). Patients with T2D 
have a 2-fold increased risk of having an ischemic stroke, with a favorable time trend over the 
last decades with the risk coming down from 6-8-fold increase (9-13). Patients with diabetes 
have higer mortality and recurrence risk (13, 14). Moreover, T2D patients are, in general, 
affected by more severe neurological impairment and have a worse recovery compared to 
non-diabetic subjects (15-17). Patients with diabetes not only have less chance of a favorable 
outcome, but are also at an increased risk of progressive deterioration after a stroke. A recent 
Swedish cohort study showed that persons with diabetes had a 50 % increased risk of 
continuing loss of independency in activities of daily living (ADL) between 3 and 12 months 
after a stroke (18).  
The prevalence of diabetes among stroke patients is high. Approximately 20 % have diabetes 
known prior to the stroke and an additional 16-24 % have previously undiagnosed diabetes 
(16, 19). The prevalence of abnormal glucose metabolism, not meeting formal criteria for 
diabetes, is even higher with only 42 % of patients having a normal glucose challenge when 
tested three months after the stroke (19). In Sweden the diabetes prevalence among stroke 
patients, according to the national stroke registry (Riksstroke) is 18% for Transitory Ischemic 
Attack patients and 23 % for stroke patients (6).  
This thesis will focus on ischemic stroke and T2D, which is the predominant form of diabetes 
worldwide. In Sweden approximately 90% of all persons living with diabetes are diagnosed 
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with T2D according to the Swedish national diabetes registry (20). Herein “diabetes” refers to 
T2D, unless otherwise specified.  
1.1.2 Hyperglycemia, stroke and outcome 
As stated above, T2D patients not only suffer strokes more often, they also recover to a lesser 
extent (15-17, 21). The presence of hyperglycemia at admission for stroke is common (16, 
22), and having hyperglycemia on arrival at hospital with an ischemic stroke is an established 
risk factor for poor outcome, measured e.g. as relief of symptoms, recovery to independent 
life or even death (14, 23-28). Notably, hyperglycemia appears to be a stronger risk factor for 
poor outcome in patients not previously diagnosed with diabetes (26, 29).  
To date the mechanisms behind the detrimental effects of hyperglycemia on the brain are still 
unclear. However, several hypotheses are suggested: activation of the hypothalamus-
pituitary-adrenal axis (HPA-axis), intracellular acidosis, extracellular glutamate 
accumulation, worsened brain edema, blood brain barrier (BBB) disruption or hemorrhagic 
transformation of the infarcted area (21, 30). Some authors have reported a correlation 
between the level of glucose on admission and the size of infarction (28). Others found no 
correlation between the perfusion deficit and admission hyperglycemia, while at the same 
time finding a 2.6-fold risk increase for poor functional outcome 6 months after the stroke 
(27). In an older study, Toni et al. reported a higher risk of death for patients with diabetes 
but no correlation between admission hyperglycemia and stroke size (31).  
Interestingly, electrophysiological disturbances in the contralateral brain hemisphere after 
stroke has been found in patients with T2D compared with non-diabetic patients (32). This 
could provide some insight into why patient with T2D recover to a lesser extent.  
1.1.3 Diabetes in experimental stroke models 
In an experimental study in rats, both diabetic (GK – Goto-Kakizaki a lean T2D model (33)) 
and normal Wistar rats, Li et al. showed that the diabetic rats, despite smaller initial cerebral 
infarcts, had more edema and hemorrhagic transformation and also performed worse on 
motor function tests (34). Stroke phenotypes in diabetic animals have been studied in other 
models of diabetes as well. Additional T2D models include the db/db and ob/ob genetic 
models involving leptin and resulting in obese, hyperinsulinemic and hyperglycemic animals. 
In these animal models of T2D, diabetic animals have more extensive strokes (35-37), 
delayed and changed inflammatory response (38) and shift the inflammatory phenotype 
towards the pro-inflammatory pathway M1 (39). Furthermore, diabetic animals have more 
infiltration of neutrophils in the infarcted area and have increased blood brain barrier (BBB) 
permeability (37). And as for humans, diabetic mice (db/db and db/+) have reduced long-
term functional outcome after stroke (39). Increased stroke and BBB breakdown have also 
been reported by Haley and Lawrence (40) in ob/ob mice. In a rat model with 
hyperinsulinemic diabetes, Zhang et al. found that the stroke volume was unchanged but the 
rats still had more pronounced deficits in sensorimotor and cognitive function after 
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experimental stroke (41). In addition, among the rats not subjected to stroke, they found 
cognitive impairment in the diabetic animals compared with the non-diabetic animals. 
Diabetes was induced at 13 months of age and this difference was seen after two months of 
diabetic condition. This lack correlation between stroke size and degree of deficit points 
towards some kind of underlying disturbance.  
Disturbances in brain function after stroke and reduced functional recovery have also been 
shown in mice with a model of type 1 diabetes (T1D), streptozotocin (STZ) induced diabetes 
(42). In this study they also found that the animals with diabetes displayed changed activation 
pattern not only in the primary somatosensory cortex area subjected to experimental stroke, 
but also in the secondary somatosensory cortex. The study was performed in 3 months old 
mice that had been diabetic for 1 month before stroke. These findings in a T1D support the 
generalizability of the negative impact on stroke from diabetes; negative effects seen in other 
studies comparing for instance GK rats with Wistar rats are not merely strain differences.  
1.1.4 Inflammation in the brain after stroke 
In the early phase of stroke, circulating inflammatory cells such as lymphocytes and 
macrophages adhere to the damaged endothelium and migrate into the brain trough the 
damaged BBB. Several inflammatory cytokines, such as interleukin (IL)-1β, IL-6 and tumor 
necrosis factor-α (TNF-α) are profoundly elevated in stroke (43-45).  
Inflammation is one of the key players in post stroke brain injury (46-49). The ischemic 
occlusion/reperfusion injury of stroke is a strong pro-inflammatory trigger. Microglia, the 
macrophage of the central nervous system, is central in the inflammatory response in the 
brain. This cell type can respond to inflammatory stimulus with different phenotypes, M1 and 
M2 (50). M1 is a classic pro-inflammatory pathway and M2 is more reparative. Early after 
stroke the response is mainly of the M2 type but after about a week gradually fades over into 
pro-inflammatory M1 response (51). Since the M1 response has been shown to be neurotoxic 
and the M2 response to promote regeneration (52), a prolongation of the M2 response has the 
potential to be beneficial to an injured brain.  
1.1.5 Interneurons 
Diabetic individuals are at increased risk from neurological impairment, with stroke being the 
most common complication in the central nervous system (CNS) (11, 12). But other CNS 
disorders are also more prevalent in diabetes, such as cognitive impairment and Alzheimer’s 
disease (53-57). Despite an established association between T2D and cognitive impairment, 
the nature of the impairment at cellular level is far from being well understood. A lot of the 
attention has been focused on hippocampus due to its importance in memory functions. 
However, patients with diabetes show many types of sensorimotor problems even without 
Alzheimer’s disease (53). An additional example is that patients with Parkinson’s disease and 
diabetes show a more rapid decline in motor dysfunction when compared with non-diabetic 
individuals (58). This demonstrates that other areas than hippocampus are likely involved.   
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1.1.5.1 GABA-ergic neurons 
Approximately 5-10 % of the neuron population of the neocortex and the deep brain structure 
striatum, which is part of the basal ganglia, consists of a set of neurons referred to as 
interneurons. They are γ-aminobuturic acid (GABA)-signaling and have important 
modulatory and controlling functions on other neurons (59, 60). Glutamic acid decarboxylase 
(GAD) is the enzyme responsible for synthesizing GABA and it exists in two isoforms 
(GAD65 and GAD67). Both are present in the brain, but it is the GAD67 that is mainly 
expressed in neuronal cell bodies (61). In a rat model study where diabetes was induced by 
streptozotocin injection (model for T1D), GAD67 was reduced in the brain and was coupled 
to depressive behavioral change (62). If T2D induces the same changes in GAD67 levels was 
before our study unknown.  
A subset of the GABA-ergic interneurons is characterized by the expression of calcium-
binding proteins, calbindin-D 28kD (CB), calretinin (CR) and parvalbumin (PV) (63). In fact, 
already in 1992 the importance of the calcium binding proteins was suggested in controlling 
and maintaining healthy CNS (64). They have the capacity to bind and buffer Ca2+, thereby 
having a protective capacity in Ca2+ overload, such as ischemic stroke (64-66). Up-regulation 
of CB expression in animal models with experimental stroke has been show to be 
neuroprotective (67). Perhaps through buffering of the excess intracellular Ca2+-levels present 
after a stroke (68). PV has been shown to play a crucial role in the development of cognitive 
 
Figure 1. Parvalbumin positive cells in the striatum of 13 months old Wistar rat. 
Photo: Martin Larsson.  
100 µm 
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impairment by disturbances in the oscillatory controlling rhythms (see below under energy 
hypothesis) through which interneurons exert control of the cortico-striatal principal neurons 
(69). CB has also been demonstrated to play a crucial role in development of Alzheimer’s 
disease (70). Lietzau et al. showed in 2016 that T2D negatively impacts the expression of CB 
in the piriform cortex, a structure involved in olfactory function, and that treatment with the 
GLP-1R agonist Ex-4 for 6 weeks dramatically increases CB expression (71).  
CB positive staining in the striatum also exists in different forms of neurons. The majority not 
being interneurons, but rather medium size spiny neurons (72) that project out towards 
substantia nigra pars reticulata (73) and participate in the regulation of the dopaminergic 
motor function control. This could be one of the ways that T2D impacts negatively on 
Parkinson’s disease (58) and could also influence motor control after ischemic injury to the 
brain. Exenatide treatment has been tested in Parkinson’s disease and found to exert 
beneficial effects on this neurodegenerative disease (74, 75).  
Interneurons have, furthermore, been described to have important impact on higher cerebral 
functions such as behavior, learning, memory and decisions making which has been reviewed 
by Pennartz et al. (76). Interneurons are a part of the striatal activity involving these higher 
cerebral functions, such as learning habits, acquiring motor skills and as modulator of motor 
function (77). Good function of these cerebral functions is crucial to achieve good recovery 
after brain injury, such as a stroke.  
1.1.5.2 Energy hypothesis of interneuron vulnerability 
Complex neuronal functions depend on precise spatial and temporal coordination of the 
neurons in cortical networks (78). This coordination is provided by network oscillations that 
enable synchronization of the neural function (79, 80). The cortical network oscillations 
depend on the inhibitory fast-spiking PV positive interneurons to produce gamma oscillations 
(30-100 Hz) (81-83). These fast spiking PV positive interneurons have, compared to other 
interneurons and pyramidal cells, been shown to have higher numbers of mitochondria and 
more cytochrome c (a crucial protein in the respiratory chain of the mitochondria), which 
both are signs of high energy expenditure (84). The gamma oscillations of the PV 
interneurons provide a fundament for information processing in the brain, and their high 
energy consumption makes them vulnerable to effects of metabolic stress (85).  
The vulnerability of the PV+ interneuron induced gamma oscillations in models of stroke has 
been demonstrated. Hippocampal ischemia by experimental stroke disrupts the gamma 
oscillations (86). In an experiment with transient global cerebral ischemia (5 min) 
GABA-ergic network activity was show to decrease in the somatosensory cortex in spite of 
recovered excitability of the neurons (87).  
1.1.5.3 Interneurons Diabetes and Stroke 
Disruptions of the gamma oscillations, network activity or Ca2+-buffering capacities of the 
interneurons provide one potential mechanism for T2D induced vulnerability to stressors 
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such as stroke and could be part of the explanation for early cognitive decline. Studies 
addressing and determining the effect diabetes has on interneurons are warranted to 
understand how diabetes affects stroke.  
 
1.2 GLP-1 
Glucagon like peptide-1 (GLP-1) is a peptide hormone that is part of the gut hormones 
potentiating the insulin response to a meal: incretins. The incretin effect refers to the finding 
by Nauck et al. that glucose given orally results in a higher insulin response compared to 
glucose given intravenously at an equal rate (88-90). The incretin effect constitutes 
approximately 50 % of the total insulin response to an oral intake (90). GLP-1 is a 30 amino 
acid long peptide synthesized and secreted from endocrine epithelial L-cells in the intestines 
in response to a meal (91-93). 
 
Figure 2. 3D-structure of GLP-1-(7-36)-amide. Image from the Research Collaboratory for 
Structural Bioinformatics Protein Data Base (rcsb.org) of PDB ID 1D0R. 
DOI: 10.2210/pdb1D0R/pdb. 
 
1.2.1 The anti-hyperglycemic action of GLP-1  
GLP-1 stimulates insulin release by binding to the GLP-1 receptor (GLP-1R) on pancreatic β-
cells. The GLP-1R is a transmembrane-spanning G-protein coupled receptor. This stimulates 
formation of cyclic AMP (cAMP) and downstream protein kinase A (PKA) that in turn leads 
to rising intracellular calcium levels and exocytosis of insulin (94, 95). For this to occur, 
concomitant hyperglycemia must also be present (96-98). Thus, the glucose lowering effect 
of GLP-1 disappears when euglycemia is reached. The binding of the GLP-1 on the 
pancreatic GLP-1R also results in increased gene transcription and insulin production, β-cell 
proliferation and reduced apoptosis (94, 99). The islet δ-cells in the pancreas also express 
GLP-1R and its activation results in increased somatostatin release (99, 100). Additionally, 
GLP-1 rapidly suppresses glucagon release from the islet α-cells which is of great benefit as 
glucagon release is often paradoxically increased in T2D (101). The suppression of glucagon 
release is likely through indirect mechanism of inhibitory signals from the β-cells and through 
somatostatin release from the δ-cells (93). Furthermore, GLP-1 receptor agonists (GLP-1RA) 
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have been shown to effectively suppress glucagon secretion in C-peptide negative T1D (102). 
This, in turn, indicates that β-cells are not necessary for the effect on glucagon suppression.  
The combined action of insulin release and glucagon suppression results in an 
antihyperglycemic effect (103).  
The GLP-1 release in T2D in response to an oral load of glucose in relation to i.v. glucose is 
less pronounced when compared to normal subjects (104). The loss of the incretin effect has 
been speculated to be an important part of the pathophysiology behind the development of 
T2D (105).  
 
1.3 GLP-1R AGONISTS AND DPP-4 INHIBITORS 
1.3.1.1 GLP-1R agonists 
Degradation of GLP-1 by DPP4 
Endogenous GLP-1 secreted by the L-cells is rapidly degraded (5 minutes) by the enzyme 
dipeptidyl-peptidase 4 (DPP-4) by means of proteolysis (106). The intact form of GLP-1 
amide (7-36) is degraded into a largely inactive form (9-36). DPP-4 exists both circulating in 
the plasma and on the endothelium (107). GLP-1 is only degraded by the DPP-4 but several 
other substrates for DPP-4 exist, e.g. gastric inhibitory peptide (GIP) and stromal cell-derived 
factor 1α (SDF1α ) (107, 108). The short half-life of native GLP-1 makes it unsuitable for use 
as an anti-diabetic drug.  
Degradation resistant GLP-1 analogues 
In the saliva from the Gila monster lizard (Heloderma suspectum) a peptide with 53 % amino 
acid homology with human GLP-1 has been found (109). This peptide, named exendin-4 
(Ex-4), is a potent agonist to the GLP-1R (109). The altered amino-acid sequence makes Ex-4 
resistant to degradation by DPP-4 and the half-life of Ex-4 is markedly prolonged in 
comparison with endogenous GLP-1, shown both in rat (110) and human (111). Synthetic 
Ex-4 is named exenatide and it is the first GLP-1R agonist available as a drug for anti-
diabetic treatment. After a subcutaneous (s.c.) injection, the maximum concentration of 
around 60 pmol/L of exenatide, is reached after approximately 2 h and its half-life is 
approximately 3.5 h (111). The maximum concentration is about three times higher than the 
fasting concentration of total GLP-1 or 30-60 times higher than the fasting active GLP-1 
amide (7-36). Exenatide was first introduced in the U.S. where it was approved in 2005. 
GLP-1R antagonist 
Ex-4 also exists in a truncated form (9-39). This works as a potent GLP-1R antagonist and 
co-administration of Ex-4 and the truncated Ex-4 (9-39) cancels out the Ex-4 effect (109). 
This is of interest in research studies.  
 8 
GLP-1 receptor agonists for clinical use 
Since the introduction of exenatide, several other GLP-1RA have reached the market with 
different mechanisms for enabling prolonged actions. Liraglutide and semaglutide are GLP-
1RA with a much greater amino-acid sequence homology with endogenous human GLP-1 
(97 % for liraglutide and 94 % for semaglutide). They have a free fatty acid attached to the 
peptide allowing binding to albumin, which thereby serves as a circulation depot and 
prolongs the half life to 12-14 hours and 1 week, respectively (92, 112). This project uses the 
first GLP-1RA to be introduced on the market, exenatide, for GLP-1R activation. This and 
other GLP-1RA on the market are reviewed in the section 1.4.2 Clinical trials of GLP-1RA 
and DPP-4i.  
1.3.1.2 DPP-4 Inhibitors 
Another approach to enhance the GLP-1R activation is inhibition of the DPP-4 degradation 
of GLP-1. Several drugs working through this mechanism are now available for clinical use. 
Inhibition of DPP-4 results in a 2-3-fold increase in GLP-1 levels in plasma after meal (113). 
In a study by Ahren et al. (113), a 4-week treatment with the DPP-4 inhibitor (DPP-4i) 
vildagliptin resulted in lower post-prandial glucose levels without a concomitant change in 
insulin levels pointing to an insulinotropic effect with enhanced release in relation to the 
glucose level. Vildagliptin also reduced the glucagon levels. These effects are all in line with 
GLP-1 action. In this thesis, the DPP-4i linagliptin was used. It has been associated with 
neuroprotection (114, 115), which is further described below under the section 1.7 DPP-4 
inhibition, Neuroprotection and Ischemic Stroke.  
1.3.2 GLP-1 effects beyond the anti-hyperglycemic action 
Receptors for GLP-1 are widespread in the body and exist not only in the primarily glucose 
controlling organs such as pancreas and liver. Apart from the pancreatic β-cells and δ-cells, 
high levels have been found on endothelial cells, myocardial cells, the gastrointestinal tract 
and the kidney (94). GLP-1 receptors have also been found in the brain, both on neurons 
(116) and on microglia (117). GLP-1 is in fact also produced in the caudal brainstem (118). 
These non-glucose functions are reviewed by Drucker (94). The cerebral effects and 
neuroprotective properties of GLP-1 are expanded on below in a separate paragraph, 
1.6 GLP-1, Neuroprotection and Ischemic Stroke.  
GLP-1R are present on both endothelium and vascular and myocardial myocytes (119). In a 
mouse model Ban et al. showed that administration of GLP-1 increased glucose uptake, 
cAMP release, left ventricular pressure and coronary artery blood flow in isolated hearts 
(119). Ban et al. also show that GLP-1 has effects not mediated directly through the GLP-1R. 
Both animal (120, 121) and clinical (122-124) studies have shown that GLP-1R activation 
results in protection from cardiac ischemia, but the exact mechanisms are still unclear. For 
example in mouse knockout models (GLP-1R -/-, globally or selective in cardiomyocytes 
(CM -/-)). Complete loss of GLP-1R (GLP-1R -/-) had no impact on the outcome of 
experimental myocardial infarcts, but administration of Ex-4 no longer provided positive 
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effect on cardiac outcome as seen in clinical studies (122-124). Furthermore, and 
surprisingly, use of a different GLP-1R agonist, liraglutide, in animals that lacked the GLP-
1R in cardiomyocytes (GLP-1R CM -/-) still resulted in cardioprotection. This indicates that 
the GLP-1R in the CM is not essential for cardiac protection (121). The field has been 
reviewed by Ussher (125). In diabetic patients with congestive heart failure the GLP-1R 
agonist exenatide has been tried for acute treatment of congestive heart failure. The patients’ 
cardiac index (cardiac output divided with body surface) increased as a result of a positive 
chronotropic effect (126). Exenatide has also been shown to increase the myocardial salvage 
index in acute coronary syndromes (122).  
It has been increasingly established, and received more attention, that inflammation has an 
important role in the development of cardiovascular disease (127). Inflammation is in fact 
one key element in understanding post stroke brain damage (46-49). GLP-1 based treatments 
Figure 3. GLP-1 actions in peripheral tissues. ©Elsevier, reproduced with permission from 
DOI: 10.1053/j.gastro.2007.03.054. 
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have been shown to reduce inflammation in vascular disease as well as neurodegenerative 
disorders such as Alzheimer’s disease and Parkinson’s disease (118, 128-130).  
Increased satiety and reduced spontaneous caloric intake by infusion of GLP-1 has been 
shown in humans, first described by Flint in 1998 (131). GLP-1 slow down gastric emptying 
(132), which could explain the increased satiety. Additionally it could be a partial explanation 
of the effects on glucose, with delayed uptake from the intestines as a result of slowed gastric 
emptying. It could also be one of the mechanisms underlying the nausea reported by 
approximately 25 % of patients on GLP-1RA as treatment for diabetes (133-135). The 
prevalence of nausea and vomiting appears to be dose-dependent (135). The reduced gastric 
emptying is believed to be via effect on vagus nerve (136) and has been shown to be 
mediated by cholinergic mechanisms (137). There is, however, also evidence of a direct 
cerebral mediation of the nausea effect (138). 
 
1.4 CLINICAL HUMAN STUDIES 
Several clinical studies throughout the years have examined prevention of cardiovascular 
disease in diabetes. The landmark studies in this category of trials are summarized in Table 1. 
The main outcome is listed, together with stroke specific outcome. Many of these trials 
showed cardiovascular benefit from the various intensified treatment strategies. They failed, 
however, to show stroke specific benefit with the exception STENO-2 (multifactorial 
intervention).  
For the GLP-1RA, on the other hand, there is evidence that such treatment can prevent stroke, 
both in epidemiologic research and clinical trials.  
Study	
(Ref)	
Year	 Study	
Size	
Intervention	 Follow	up	
(years)	
Primary	
outcome	
Primary	outcome	
HR	(95	%	CI)	
Stroke	
outcome	
Stroke	specific	
outcome	
HR/RR	(95	%	CI)	
UKPDS	
(139)	
1998	 3	867	 Intensive	
treatment	
10	 Comb.	of	
macro	and	
micro	
0.88	(0.79-0.99)		
(microvasc	
reduction,	macro	
neutral)	
Stroke	 1.11	(0.81-1.51)	
ADVANCE	
(140)	
2008	 11	140	 Intensive	
glucose	
control	
5.0	 Comb.	of	
macro	and	
micro		
0.90	(0.82-0.98)	 Non-fatal	
stroke	
1.02	(0.85-1.24)	
ACCORD	
(141)	
2008	 10	251	 Intensive	
treatment	
3.5	 MACE	 0.90	(0.78-1.04)	 Nonfatal	
stroke	
1.06	(0.75-1.50)	
STENO-2	
(142)	
2008	 160	 Multifactorial	
intervention	
13.1	 Death	 0.54	(0.32-0.89)	 Stroke	 RR	0.2	(CI	not	
reported)	
VADT	
(143)	
2009	 1	791	 Intensive	
treatment	
5.6	 MACE	 0.88	(0.74-1.05)	 Stroke	 0.78	(0.48-1.28)	
ORIGIN	
(144)	
2012	 12	537	 Basal	insulin	 6.2	 MACE	 1.02	(0.94-1.11)	 Stroke	 1.03	(0.89-1.21)	
Table 1. Landmark studies of cardiovascular prevention in type 2 diabetes with stroke specific 
outcome. 
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1.4.1 Epidemiologic GLP-1RA and DPP-4i studies  
Epidemiologic studies support stroke-preventing effects of GLP-1RA treatment in patients 
with T2D. The first epidemiologic study was published in 2011 (145) and has been supported 
by a larger retrospective observational study (146). These two studies show large risk 
reduction of cardiovascular events with approximately 20 % and 50 % respectively (145, 
146). In the first study, by Best et al., only a combined outcome measure of cardiovascular 
events was reported as outcome. But in the second, more specific outcome data was reported 
for heart failure, myocardial infarction and stroke individually. In the second study, by Paul et 
al., exenatide treated patients were compared with T2D patients not on exenatide. Data was 
reported for patients in three groups: exenatide without insulin, exenatide with insulin and 
insulin without exenatide. Stroke was reported separately with comparisons between patients 
treated with exenatide vs. patients treated with exenatide + insulin (HR 0.50; 95 % CI 0.28-
0.84) and exenatide + insulin vs. insulin (HR 0.38; 95 % CI 0.27-0.54) (146). Oral anti 
diabetic agents were used in both groups. The results were unchanged even if patients with 
previous cardiovascular disease were excluded. In this type of retrospective cohort study 
there is a risk of confounding by indication, i.e. that there is a reason that determined if a 
patient received exenatide or not which in turn is the real reason behind the observed 
differences. One such confounder could be that younger patients were more likely to get the 
new treatment (exenatide). In fact exenatide treated patients were younger. They tried to 
adjust for this and several other potential confounders, and also used the statistical method 
called propensity score matching to further try to adjust for this. The risk of confounding 
must, however, be kept in mind when interpreting these studies.  
In an epidemiologic study on the use of DPP-4i in T2D patients with end stage renal disease 
(ESRD) on dialysis treatment Chan et al. found a very large risk reduction for all cause 
mortality (HR 0.43; 95 % CI 0.39-0.47) and also marked reduction in stroke incidence (HR 
0.77; 95 % CI 0.61-0.97) (147). Propensity score was used for matching and mean follow up 
time was 1.8 years, which is in line with the follow up time in the large clinical studies 
SAVOR, TECOS and EXAMINE. This study was, in contrast with the clinical RCTs, 
performed in patients with ESRD and the rate of events was high. The most common DPP-4 
inhibitor in the study was sitagliptin. 
1.4.2 Clinical trials of GLP-1RA and DPP-4i 
Several clinical studies of both GLP-1R agonists and DPP-4 inhibitors have recently been 
published and we now have quite a substantial body of evidence showing cardiovascular 
safety from these drugs and in some cases also good protection against cardiovascular disease 
(CVD) including stroke. Two trials have, apart from overall cardiovascular benefit, also 
demonstrated stroke specific benefit, SUSTAIN-6 (148) and REWIND (149).  
For the DPP-4 class several large clinical randomized cardiovascular safety trials have been 
finalized in the last couple of years. These include the DPP-4 inhibitors saxagliptin (SAVOR) 
(150), sitagliptin (TECOS) (151), alogliptin (EXAMINE) (152), linagliptin (CARMELINA) 
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(153) and CAROLINA (154). These large studies were primarily constructed as 
cardiovascular safety studies with placebo comparator. They all, in short, show 
cardiovascular safety, but there is no positive protective effect in terms of cardiovascular 
outcome. Worth mentioning is also that in the SAVOR study there was an increase in 
hospitalization for heart failure that did not occur in the other trials. No reduction in stroke 
incidence was seen in these studies. At the same time it must be kept in mind that it is not the 
same thing to influence the occurrence of a cardiovascular event such as a stroke and to 
modulate and potentially mitigate the negative outcome of a stroke (i.e. to be neuroprotective 
in the context of a stroke).  
Linagliptin was compared with an active comparator (glimepiride) in the longest existing 
clinical trial of a DPP-4 inhibitor, the CAROLINA trial (154). It randomized 6 033 patients 
with T2D and met the primary endpoint of non-inferiority of linagliptin compared to 
glimepiride, but not superiority. It was, however, safe from a cardiovascular perspective. 
For GLP-1R agonists, six major clinical trials have been published: lixisenatide (ELIXA) 
(155), liraglutide (LEADER) (156), semaglutide (SUSTAIN-6) (148), albiglutide 
(HARMONY) (157), a once-weekly preparation of exenatide (EXSCEL) (158) and 
dulaglutide (REWIND) (149). None of the study protocols in these trials allowed for 
assessment of functional outcome in the patients that suffered ischemic stroke. Only data on 
time to first event, and the nature of the event, was recorded.  
The results, in summary, show a preventive effect of GLP-1RA against incident stroke. 
Below some of the trials are elaborated on. The GLP-1RA and DPP-4 trials are summarized 
in Table 2, with a Forest plot visually plotting the main outcome and the stroke specific 
outcome of the GLP-1RA trials in Figure 4. Overall estimates in the Forest plots were 
calculated by combining the studies weighted with inverse-variance.  
1.4.2.1 LEADER 
The LEADER-study (156) was originally planned as a cardiovascular safety trial of 
liraglutide and the primary endpoint was non-inferiority in comparison with placebo on a 
composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction or 
nonfatal stroke. A total of 9 340 patients at high risk for cardiovascular events (established 
cardiovascular disease or chronic heart failure) were randomized and the average follow up 
time was 3.8 years. HR for the primary outcome was 0.87 95 % CI 0.78-0.97. P-value for 
non-inferiority was <0.001 and p=0.01 for superiority.  
The LEADER study is the first clinical GLP-1RA trial to show a reduction of cardiovascular 
events in T2D. The risk reduction for nonfatal stroke was 11 %, but not significant (HR: 0.89, 
95 % CI: 0.72-1.11).  
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1.4.2.2 SUSTAIN-6 
SUSTAIN-6 (148) was also originally designed as a non-inferiority study comparing 
semaglutide with placebo. Semaglutide is a GLP-1R agonist that closely resembles liraglutide 
(97 % homology) but has small amino acid modifications and a different fatty acid attached 
to it making the clinical half-life of semaglutide markedly prolonged to approximately 1 week 
(112). This allows for a once-weekly administration.  
SUSTAIN-6 included high-risk individuals with established cardiovascular disease, chronic 
heart failure or chronic kidney disease. The main outcome was a three point MACE of 
cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. There was a 26% 
reduction in the primary endpoint (HR 0.74, 95% CI of 0.58-0.95). P for non-inferiority was 
<0.001, p for superiority was 0.02.  
The SUSTAIN-6 showed, similar to the LEADER-study, solid evidence for cardiovascular 
risk reduction. More interesting from a stroke perspective is that SUSTAIN-6 showed a 
pronounced stroke preventive effect. The risk reduction was 39 % for nonfatal stroke (HR 
0.61, 95 % CI 0.38-0.99). This marked stroke-preventive effect of semaglutide may be 
indicative of a specific neuroprotective action but this remains to be elucidated. There was no 
data on functional outcome of the stroke. 
1.4.2.3 EXSCEL 
EXSCEL is a randomized controlled trial of once-weekly exenatide compared with placebo. 
14 752 patients were randomized with a median follow up time of 3.2 years (158). Primary 
analysis was non-inferiority for major cardiovascular events, which the study achieved 
(p<0.001). Secondary analysis was for superiority, which they did not show. HR 0.91, (95 % 
CI 0.83-1.00), p=0.06. HR for fatal or non-fatal stroke was 0.85 with a 95 % CI of 0.70-1.03.  
1.4.2.4 HARMONY 
HARMONY is a randomized controlled trial of albiglutide given once-weekly compared to 
placebo (157). 9 463 patients were included and followed for a median of 1.5 years. The trial 
demonstrated non-inferiority with a p<0.0001 and also superiority on the primary composite 
endpoint of cardiovascular death or non-fatal cardiovascular events such as myocardial 
infarction and stroke: HR 0.78 (95 % CI 0.68-0.90). The stroke specific outcome of fatal or 
non-fatal stroke was not significant with a HR of 0.86 (95 % CI 0.66-1.14), p=0.30. Of note 
is that this overall superiority outcome was achieved after the short study period of 1.5 years. 
The study period was actually prolonged after the primary objective was met in order to allow 
for potential adverse events to surface.  
1.4.2.5 REWIND 
REWIND is a randomized controlled trial of once-weekly dulaglutide compared with placebo 
in patients with T2D above the age of 50 years (149). This study differs somewhat from the 
other GLP-1RA trials in that it included both patients with established cardiovascular disease 
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(31.5 %) and a high proportion of patients with risk factors without previous CVD (68.5 %). 
It was a superiority trial with the primary outcome defined as first occurrence of a MACE. 
HR for primary outcome was 0.88, (95 % CI 0.79-0.99), p=0.026. All components of the 
combined outcome measure (MACE) showed consistent results and the stroke specific 
outcome of non-fatal stroke showed a HR 0.76 (95 % CI 0.61-0.95), p=0.017. No data was 
presented on functional outcome stroke.  
Table 2. Clinical trials investigating cardiovascular effects of GLP-1 RA and DPP-4i 
treatment on patients with T2D. *Primary outcome used one-sided CI, p<0.001 for 
noninferiority, p=0.32 for superiority. MACE: major adverse cardiovascular event, HR: 
Hazard ratio, CI: confidence interval. 
A
 
B
 
Figure 4. Forest plots of main outcome (A) and stroke specific outcome (B) in GLP-1RA 
cardiovascular outcome trials. Bars indicate 95 % CI.  
1 50.5
Overall
ELIXA
SUSTAIN-6
LEADER
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HARMONY
REWIND
Favors treatment <-  HR  -> Favors placebo
1 50.5
Overall
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LEADER
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HARMONY
REWIND
Favors treatment <-  HR  -> Favors placebo
	 Study	 Drug	 Author/	Year	 Study	
Size	
Avg.	
follow	up	
(years)	
Primary	
outcome	
Primary	
outcome	HR	
(95	%	CI)	
Stroke	specific	
outcome	HR	
(95	%	CI)	
GLP-1	 REWIND	
(149)	
Dulaglutide	 Gerstein,	
2019	
9	901	 5.4	 MACE	 HR	0.88		
(0.79-0.99)	
0.76		
(0.61-0.95)	
	 HARMONY	
(157)	
Albiglutide	 Hernandez,	
2018	
9	463	 1.5	 MACE	 HR	0.78		
(0.68-0.90)	
HR	0.86		
(0.66-1.14)	
	 EXSCEL	
(158)	
Exenatide	 Holman,	2017	 14	752	 3.2	 MACE	 HR	0.91		
(0.83-1.00)	
HR	0.85		
(0.70-1.03)	
	 LEADER	
(156)	
Liraglutide	 Marso,	2016	 9	340	 3.8	 MACE	 HR	0.87		
(0.78-0.97)	
HR	0.86		
(0.71-1.06)	
	 SUSTAIN-6	
(148)	
Semaglutide	 Marso,	2016	 3	297	 2.1	 MACE	 HR	0.74		
(0.58-0.96)	
HR	0.61		
(0.38-0.99)	
	 ELIXA		
(155)	
Lixisenatide	 Pfeffer,	2015	 6	068	 2.1	 MACE	 HR	1.02		
(0.89-1.17)	
HR	1.12		
(0.79-1.58)	
DPP-4	 CAROLINA	
(154)	
Linagliptin	 Rosenstock,	
2019	
6	042	 6.3	 MACE	 HR	0.98	
(0.84-1.14)	
HR	0.86	
(0.66-1.12)	
	 CARMELINA	
(153)	
Linagliptin	 Rosenstock,	
2019	
6	979	 2.2	 MACE	 HR	1.02		
(0.89-1.17)	
HR	0.91		
(0.67-1.23)	
	 SAVOR	
(150)	
Saxagliptin	 Scirica,	2013	 16	492	 2.1	 MACE	 HR	1.00		
(0.89-1.12)	
HR	1.11		
(0.88-1.39)	
	 TECOS		
(151)	
Sitagliptin	 Green,	2015	 14	671	 3.0	 MACE	
(4-point)	
HR	0.98		
(0.89-1.08)	
HR	0.97		
(0.79-1.19)	
	 EXAMINE	
(152)	
Alogliptin	 White,	2013	 5	380	 3.3	 MACE	 HR	0.96		
(≤1.16*)	
HR	0.91		
(0.55-1.50)	
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1.5 TREATMENTS IN STROKE AND DIABETES 
To prevent the occurrence of cardiovascular events and death is not the same thing as 
improving outcome after an event. Diabetes affects the outcome after stroke and influence the 
effect treatments, such as rtPA, have.  
1.5.1 Treatment with rtPA in the light of hyperglycemia and outcome 
During the last decades intravenous treatment with recombinant tissue plasminogen activator 
(rtPA) has been established as standard treatment for patients with ischemic stroke as a means 
to dissolve the formed thrombus causing the tissue asphyxia. The treatment must be started 
within 4.5 h of stroke onset with a number needed to treat (NNT) of 4.5 if given at 1.5 h post 
onset and a NNT of 14 when given at 4.5 h post onset in order to achieve an excellent 
functional outcome defined as modified Rankin Scale (mRS) 0-1 (159). The use of rtPA is, 
however, associated with a significant risk of symptomatic intracranial hemorrhage (SICH); 
approximately 1-10 %, dependent on a number of risk factors including time from onset to 
treatment and also on the definition used (159-163). The risk is increased when 
hyperglycemia is present, regardless of diabetes or not (163-165).  
There is, furthermore, evidence that hyperglycemia in the acute phase is detrimental, 
regardless of rtPA-therapy but particularly so if reperfusion with rtPA is achieved (166, 167). 
Using diffusion-weighted imaging Ribo et al. found that the ischemic lesion growth was 2.7 
times faster in the presence of hyperglycemia during occlusion (166). Hyperglycemia has 
even been indicated to counteract the beneficial effects of reperfusion (167). In a study by 
Poppe et al. on stroke patients treated with rtPA, admission hyperglycemia was associated 
with an increase in the relative risk of death within 90 days (RR 1.5 [95 % CI 1.2-1.9]), SICH 
(RR 1.69 [95 % CI 0.95-3.0]) and decreased chance of favorable outcome (RR 0.7 [95 % CI 
0.5-0.9]) (165). The risks for death, SICH and unfavorable outcome were incremental with 
increasing admission glucose, even within the non-diabetic group.  
A study examining more than 16 000 individuals treated with rtPA for ischemic stroke 
included in the global Safe Implementation of Treatments in Stroke International Stroke 
Thrombolysis Register (SITS-ISTR) [www.sitsinternational.org] showed a strong association 
with death, SICH and unfavorable outcome with increasing hyperglycemia (164). The 
association was of dose-response type between risk and the level of hyperglycemia. The 
association was stronger in patients without previously diagnosed diabetes. In a study by 
Mazya from the SITS-ISTR, a clinical scoring system was developed to predict the risk of 
SICH; the odds ratio (OR) for SICH in hyperglycemia (defined as >10 mmol/L) was 2.1 
(95 % CI 1.7-2.6, p<0.001) (163). Notably, in this clinical scoring model, the only potentially 
modifiable risk factors in preparation for rtPA treatment were hyperglycemia and 
hypertension. The other risk factors were: aspirin and/or clopidogrel therapy, high National 
Institutes of Health Stroke Scale (NIHSS) score, old age, high weight, onset to treatment > 3h 
and history of hypertension.  
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1.5.2 Antidiabetic treatment in acute stroke 
The evidence points to a detrimental effect of hyperglycemia in the acute phase of ischemic 
stroke and that the beneficial effect of rtPA is diminished. Thus, achieving normoglycemia in 
the acute phase, preferably before recanalization therapy, has potential for a positive effect 
for the patients with ischemic stroke. Randomized clinical trials aiming for euglycemia with 
intensive insulin treatment in hyperglycemic stroke patient have so far been unable to show 
benefit for intensive insulin treatment in the acute phase (168). Additionally, the studies have 
often been started at a late time point (see Table 3). 
In the GIST-UK study by Gray et al., where insulin-potassium-glucose infusion was used in 
patients with stroke, no benefit was shown despite achieving lower plasma glucose (169). 
The treatment was, however, on average started 13 h after stroke onset and there was 
sustained hypoglycemia (>30 minutes below 4.0 mmol/L) in 15 % of the patients (169). The 
SHINE-trial published 2019 is the most recent of these insulin trials (170). Treatment was 
started somewhat earlier, at 8.6 hours, but did not either show any benefit from insulin 
treatment. In fact the Cochrane collaboration has in a systematic review of this field of 
research concluded that maintaining glucose in a narrow normal range does not provide any 
benefit in terms of neurological outcome or survival (171).  
A potential explanation for the lack of effect in these intensive insulin trials may be that they 
have investigated glucose lowering in stroke at a too late time point, (8.6 and 13.3 in the 
hours after stroke onset in the large trials) (169, 170); at which a majority of the neurons in 
the penumbra are probably highly ischemic and/or already dead.  
Furthermore, in the intensive insulin treatment studies, a high frequency of hypoglycemia 
was reported in the insulin intervention groups. Hypoglycemia may be especially detrimental 
to neurons under ischemic stress. In Table 3 trials investigating intensive glucose treatment in 
stroke patients with time to treatment initiation and occurrence of hypoglycemia are listed. 
Most do not report functional outcome, except Johnson 2019 and Gray 2007, which are both 
neutral.  
Intervention on multiple targets at the same time has also been proposed as a way of 
achieving transferability of neuroprotective strategies from animal models to human stroke 
patients (172). Such as starting a therapy early, with a glucose normalization treatment that 
does not carry with it risk for hypoglycemia and at the same has neuroprotective properties 
even in euglycemic conditions. This type of strategy could be of paramount importance for 
neuroprotection to be efficacious. 
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Reference Patients  N Intervention Time to 
treatment 
onset (h) 
Hypoglycemia 
cut off  
(mmol/L)               Proportion 
Bruno,  
2004 (173) 
Ischemic stroke <12 h 24 Iv and sc insulin Not reported <3.0 46 % 
Walters,  
2006 (174) 
Ischemic stroke <24 h 13 Iv insulin 9.1 <3.5* 23* 
Gray,  
2007 (169) 
All stroke <24 h 460 Iv glucose-
potassium-insulin 
13.3 <4.0 for >30 
min.  
15.7 % 
Bruno,  
2008 (175) 
Ischemic stroke <12 h 31 Iv insulin Not reported 3.3 35 % 
Kreisel,  
2009 (176) 
Ischemic stroke <24 h 20 Iv insulin 17.1 3.3 23 events 
Kruyt,  
2010 (177) 
Ischemic stroke <24 
h, tube & iv insulin, iv 
insulin only 
10 
 
13 
Tube feeding & iv. 
insulin or  
iv insulin 
Not reported 3.5 
 
3.5 
20  
 
30.7 % 
Johnston,  
2009 (178) 
Ischemic stroke <24 
h, Intensive control & 
moderate control  
24 
 
25 
Iv insulin 12.3  
 
10.6 
<3.1 30 %  
 
4 % 
McCormick,  
2010 (179) 
Ischemic stroke <24 h 25 Iv insulin 20.8 4.0 76 % 
Staszewski,  
2011 (180) 
Ischemic stroke <12 h 26 Iv insulin 6 <3.3 8 % 
Rosso,  
2012 (181) 
Ischemic stroke <6 h 85 Iv insulin Not reported <3.0 
<3.6 
5.7 % 
19.5 % 
Johnston,  
2019 (170) 
Ischemic stroke <12 
h, Glucose >6.1 if 
T2D, >8.8 if no DM. 
T1D excluded.  
581 Iv insulin, 
computer aided.  
Median 
8.6h.  
Severe:  <2.2 
 
2.6 % 
Aborted 
treatment in 
144 patients: 
39 % due to 
hypoglycemia 
Table 3. Trials of intensive glucose control with insulin in stroke. N denotes number of 
patients in intensive treatment group. *Not presented in article original article, found in 
review by Kruyt from 2010, (168). 
 
1.6 GLP-1, NEUROPROTECTION AND ISCHEMIC STROKE  
In an ischemic stroke, the affected area can be divided in a core and a penumbra. The core is 
the area of the brain where the cells die very quickly. The penumbra is the surrounding area 
of the brain where some circulation is still present which keeps the neurons alive for up to 6 
to 8 hours and make them potentially salvageable if an intervention is put in place, otherwise 
it will progress to infarction (182). So far pre-clinically promising therapies targeting the 
neurons of the penumbra have failed when attempted in clinical trials (183). This could be 
due to many different factors such as difference in underlying biology as well as timing of 
administration in relation to stroke, dose or route of administration. Experimental animal 
studies are, furthermore, often performed in animal models without important comorbidities 
such as diabetes or performed in young animals and thereby differing substantially from the 
clinical situation with old and often comorbid patients.  
1.6.1.1 GLP-1 can pass the Blood Brain Barrier 
Endogenous GLP-1 has been shown to pass the BBB by means of diffusion in mouse (184). 
The GLP-1R analogue exendin-4 has been shown to rapidly pass the BBB, but the rate might 
be limited in high concentrations (185). Additionally there is also evidence that the GLP-1R 
analogues liraglutide and lixisenatide can pass the BBB (186). Passage of the BBB has thus 
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been demonstrated in rodents, but not shown in man. GLP-1 receptors are expressed in the 
brain (116, 187). 
1.6.2 GLP-1 treatment in experimental stroke models 
GLP-1 based therapies have been studied and shown to exert neuroprotective effect in stroke 
models. Importantly, most studies on neuroprotection in the central nervous system (CNS) 
with GLP-1RA and DPP4i have been performed under non-diabetic conditions. One of the 
first studies to demonstrate neuroprotective effects of Ex-4 was a study by Li et al. from 2009 
where they saw a reduction in stroke volume and improvement in locomotor activity after an 
experimental model of stroke (MCAO – middle cerebral artery occlusion) in Sprague-Dawley 
rats (188). An interesting finding in this study was that the neuroprotective effect was lost in 
GLP-1R -/- knockout mice indicating that the effect is receptor-dependent. However, a major 
limitation of this study in terms of clinical relevance was the timing of administrating of Ex-
4: before induction of the stroke. Moreover, the route of administration – direct intracerebral 
injection into a lateral ventricle is not applicable in a clinical setting. Nevertheless, this study 
demonstrated the neuroprotective potential of GLP-1R agonists.  
Ex-4 given peripherally has also been shown to be neuroprotective in the experimental stroke 
model MCAO. In a study from our group, by Darsalia et al., pretreatment with intra 
peritoneal (i.p.) Ex-4 for four weeks pre stroke was effective in reducing the stroke volume 
and increased the number of surviving neurons (189). The study also showed effect on 
decreased inflammatory microglia infiltration and increased stem cell proliferation in diabetic 
rats (GK). The effect was dose dependent and discernible at a clinical dosing of 0.1 μg/kg. 
This study showed that clinical dosing and peripheral administration could give 
neuroprotection in stroke, but the treatment was started before the stroke making it a positive 
study for those on the drug already but of limited value for someone not on the drug and 
suffering a stroke.  
Additionally, pre-stroke treatment with clinical dosing of Ex-4 (0.1 μg/kg) has been shown to 
have neuroprotective capabilities independent of effect on glucose in the aforementioned 
study by Darsalia et al. (189).  
Briyal et al. evaluated the effect of Ex-4 as pretreatment before (7 days) MCAO on stroke 
volume and also on markers of oxidative stress and reported a reduction in stroke volume and 
reduced oxidative stress (190). The effect of Ex-4 has also been shown in gerbils in a 
hippocampal cerebral ischemia model (191).  
Demonstration of neuroprotective efficacy from GLP-1RA treatment has also been shown 
when given post stroke. Teramoto et al. showed that intravenous administration of Ex-4 
given immediately after, or 1 h, after reperfusion resulted in reduced stroke volume and 
improved functional outcome (192). In this study the effect was lost if Ex-4 was given 4 h 
post stroke when measured as stroke volume.  
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The GLP-1R analogue liraglutide has also been tested by Briyal et al. (193) and been shown 
to be neuroprotective and to reduce apoptosis and oxidative stress when used as a 2-week pre-
treatment before MCAO. The effect was seen both in diabetic and non-diabetic animals. As 
model of diabetes they used STZ (a model of T1D). This implies insulin independent, and 
perhaps, glucose independent effects of liraglutide. Liraglutide has been shown to be 
neuroprotective with reduced infarct volume and up-regulation of vascular endothelial growth 
factor (VEGF) in the cortex, but not in the striatum (194) in non-diabetic rats (Wistar). The 
once-weekly preparation semaglutide (with 97% sequence homology with liraglutide), has 
also in a recent publication from 2019 been shown to be neuroprotective with reduced infarct 
size and better neurological recovery (195).  
Intranasal administration of Ex-4 has also been shown to be neuroprotective (non-diabetic 
mice, MCAO) (196). In this study, the animals were pre-treated 7 days before MCAO. The 
authors claim the effect to be through anti-apoptotic pathways.  
Another way of stimulation the GLP-1R has been published regarding neuroprotection. 
Zhang et al. (197) have recently reported that a quinoxaline; 6,7-dichloro-2-methyl-sulfonyl-
3-N-tert-butylaminoquinoxaline (DMB) that acts as an allosteric modulator of the GLP-1R 
and works as an agonist on the receptor also confers neuroprotection. In this study DMB was 
given orally 30 minutes before MCAO and compared with Ex-4 that was injected 30 min 
before MCAO. DMB showed neuroprotection, which also was demonstrated with Ex-4 (40 μg/kg). The same group has furthermore published a study demonstrating anti-stroke effects 
using a long-acting polymeric GLP-1, pro-GLP-1, to activate the GLP-1R (198).  
In summary there are preclinical studies on treatment of acute stroke with GLP-1R agonists. 
Either by pretreatment before stroke (188-191, 193, 196-198), or as acute treatment after the 
onset (192, 194, 195, 199).  
 
1.7 DPP-4 INHIBITION, NEUROPROTECTION AND ISCHEMIC STROKE  
As with GLP-1R agonists, DPP-4i has been studied as a neuroprotective drug. There is 
evidence that this strategy has neuroprotective potential but not at the same level as for GLP-
1R agonists. A proof of concept study was when intracerebral administration of a DPP-4 
inhibitor in 2012 was shown to reduce the cortical infarct volume in experimental stroke with 
endothelin induced MCAO (eMCAO) (200). The DPP-4i linagliptin has been shown to 
increase the number of surviving neurons after MCAO in the cortex of mice in a study where 
linagliptin was given during 4 weeks before and 3 weeks after MCAO (115). In this study the 
neuroprotective effect by linagliptin was seen both in normal and diabetic mice, pointing 
towards glucose independent mechanisms. A different DPP-4 inhibitor, alogliptin, has also 
been shown to be neuroprotective if given 3 weeks before induction of experimental stroke 
(201). The authors measured brain-derived neurotrophic factor (BDNF), which was increased 
in the treated group and they speculate if this is part of the mechanism behind the 
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neuroprotective effect, potentially via up-regulation of the number of GABA-ergic synapses 
where BDNF has been found to play a role (202). BDNF has also been shown to enhance the 
GABA release (203). GABA and its role in signaling is discussed further below in the 
interneurons section.  
Another potential mechanism through which DPP-4 inhibitors might have neuroprotective 
properties is stimulation of neural stem cell proliferation. After a stroke, neurogenesis has 
been shown to take place in the striatum, but some of the new neurons are probably 
preformed neuroblasts that could remigrate from the olfactory bulb to the striatum and 
replace dead neurons post stroke (204, 205). In Regulatory Peptides Darsalia et al. show that 
the DPP-4i linagliptin enhances neural stem cell proliferation after experimental stroke (206). 
This effect was, however, only seen in diabetic animals and the effect was not seen in vitro 
indicating indirect effects (pathways).  
Treatment with the DPP-4i linagliptin has been shown to, irrespective of glycemic control, 
improve cerebrovascular dysfunction and remodeling in GK-rats (207). Additionally, high-
dose-treatment with linagliptin (10 mg/kg/day) in db/db mice was able to improve 
performance in cognitive tests (water maze and passive avoidance) after cerebral ischemia 
(208). This occurred without a concomitant reduction in blood sugar. The animals were 
highly hyperglycemic throughout the study (glucose well in excess of 20 mmol/L), pointing 
to other mechanisms than regulation of glycemia as the main effect mediator.  
SDF-1α is, in addition to GLP-1, a substrate for DPP-4 and has been shown to be important 
in the efficacy of DPP-4i (209-213).  
The efficacy of DPP-4i in affecting the inflammatory polarization of macrophages also been 
studied. Zhuge et al. have tested the DPP-4i linagliptin and sitagliptin in young mice given 
high fat diet (HFD) to become obese and simulate the T2D metabolic syndrome patient (214). 
They showed that the DPP-4i shift the M1/M2 polarization towards the reparative M2. 
Linagliptin was more effective than sitagliptin. The effect was studied in fat and liver tissue 
which is not directly transferable to stroke, but it is interesting since the effect has been 
shown in GLP-1R treated diabetic mice (199).  
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1.8 SUMMARY OF INTRODUCTION 
• Diabetes is a strong risk factor for neurological complications, with stroke as the most 
common CNS complication.  
• Recovery after an ischemic stroke is impaired in T2D patients.  
• The risk of complications to acute stroke treatment with rtPA is higher in 
hyperglycemic patients. 
• Trials of glucose normalization with insulin have failed to show patient benefit.  
• GLP-1RA treatment is proven to reduce ischemic stroke incidence. 
• GLP-1-based therapies are safe and have the potential for pleiotropic, non glucose-
mediated, effects that protect against ischemic stroke. 
• Impaired interneuron function could be one of the explanations behind why diabetes 
causes CNS-complications and why persons with diabetes have worse outcome after 
stroke.   
• GLP-1RA has potential to amend some of the impairments in interneuron functions.  
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2 AIMS OF THESIS AND INDIVIDUAL STUDIES 
2.1 OVERALL AIM 
To establish the role of GLP-1 in ischemic stroke and to determine whether GLP-1 based 
treatments can be used to counteract metabolic changes in patients with stroke and mitigate 
the detrimental effects of ischemic stroke.  
2.1.1 Study 1 Exendin-4 in mice 
To determine the neuroprotective efficacy of GLP-1RA exendin-4 given after stroke and to 
study its effect on the inflammatory response. 
2.1.2 Study 2 Linagliptin in mice 
To determine the neuroprotective efficacy of the DPP-4 inhibitor linagliptin given after stroke 
and to establish if the effect was dependent on the GLP-1 receptor. 
2.1.3 Study 3 GABA-ergic neurons in rats 
To establish if, and how, aging and T2D affect cortical and striatal GABA-ergic neurons. The 
aim was also to determine if potential changes could be counteracted by treatment with the 
GLP-1RA Ex-4. 
2.1.4 Study 4 OGTT among rtPA treated Stroke patients 
To determine if endogenous GLP-1 secretion is altered in the acute phase of stroke and if the 
GLP-1 levels in acute stroke are correlated to functional outcome of the stroke.  
2.1.5 Study 5 Exenatide in ambulance 
To evaluate the feasibility of starting exenatide treatment of hyperglycemia in the ambulance 
in patients with suspected stroke.   
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3 MATERIAL AND METHODS 
3.1 STUDY DESIGN 
The thesis is based on a combination of experimental animal studies and human clinical 
studies. The different studies had the following designs.  
3.1.1 Study 1 
An experimental animal study. A total of 128 male C57Bl mice were used in the experiments. 
It was divided into four sub-studies to test: 
1. The potential neuroprotective efficacy of 5 μg/kg Ex-4 started 1.5 and 3 hours post 
MCAO on 2 months old mice. (n=31) 
2. The potential neuroprotective efficacy of 50 μg/kg Ex-4 started 1.5, 3 and 4.5 hours 
post MCAO on 2 months old mice. (n=47) 
3. The potential neuroprotective efficacy of 50 μg/kg Ex-4 started 1.5 and 3 hours post 
MCAO on mice that were obese and diabetic by exposure to HFD for 12 months. 
(n=27) 
4. The potential effect of 50 μg/kg Ex-4 started 1.5 hours post stroke on the 
inflammatory response after MCAO on 2 months old mice. (n=23) 
Treatment was continued in all sub-
studies with 0.2 μg/kg Ex-4 daily 
for 7 days until sacrifice except for 
the inflammation sub-study that 
was ended at 3 days (to be 
concurrent with M2 microglia 
response after stroke).  
The animals intended for 
immunohistochemistry were deeply 
anesthetized and perfused transcardially with saline followed by paraformaldehyde (4%, ice 
cold). Animals intended for tissue collection were perfused with saline only.  
3.1.2 Study 2 
An experimental animal study. A total of 117 male mice were used in the experiments. 35 
glp-1-/- and 82 wild type (C57Bl). The glp-1r-/- mice have a mutation in the gene for the GLP-
1 receptor making it inactive. They develop normally, have lower levels of circulation insulin 
and have higher glucose levels during an OGTT (215).  
The study was divided in four sub-studies. The objective was to test: 
1. Neuroprotective efficacy of linagliptin given acutely in comparison with chronic 
treatment before stroke. 50 mg/kg of linagliptin (n=12) or vehicle (n=13) was 
Figure 5. Experimental design Study 1. MCAO: middle 
cerebral artery occlusion, Ex-4: exendin-4, HFD: High 
fat diet, m: months, d: days, b.i.d: twice daily 
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injected intravenously and MCAO surgery started immediately after (30 minutes of 
occlusion was used). For the chronic setting p.o. treatment of linagliptin 10 mg/kg (n= 
9) or vehicle (n=10) was used.  
2. Neuroprotective efficacy of linagliptin in the absence of the GLP-1 receptor. 
Knockout mice glp-1r-/- were used. Chronic treatment with linagliptin (n=9) or vehicle 
(n=7) was used according to the same protocol as in sub-study 1. MCAO was 
performed with 30 minutes of occlusion.  
3. Neuroprotective efficacy of Ex-4 in the absence of the GLP-1 receptor. Knockout 
mice glp-1r-/- were used. Ex-4 0.1	μg/kg intraperitoneally (i.p.) (n=12) or vehicle 
(n=7) was given for four weeks before MCAO and three weeks after. For comparison 
eleven wild type mice were given Ex-4 (n=5) or vehicle (n=6) according to the same 
protocol. MCAO was performed with 30 minutes of occlusion.  
4. The effect of linagliptin on cerebral GLP-1 levels and DPP-4 activity. 10 weeks 
old mice were chronically treated (n=19) for four weeks of linagliptin or vehicle 
before sacrifice or given acute treatment (n=8) with linagliptin iv. or vehicle and 
sacrificed after 4 hours.  
The animals intended for immunohistochemistry were deeply anesthetized and perfused 
transcardially with saline followed by paraformaldehyde (4 %, ice cold). Animals intended 
for tissue collection were perfused with saline only.  
Figure 6. Experimental design Study 2. MCAO: middle cerebral artery occlusion, w: weeks 
i.p.:intraperitoneal, WT: wild type mice, GLP-1r -/-:GLP-1 receptor knockout mice.  
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3.1.3 Study 3 
An experimental animal study. A total of 43 rats were used (31 GK-rats and 12 Wistar rats). 
The experiment was divided into two sub-studies to test: 
1. The effect of T2D and aging 
on GABA-ergic neurons. 13 
months old GK and Wistar 
(non diabetic) rats were 
compared to 3 months old 
GK and Wistar rats.  
2. The potential of Ex-4 to 
reverse the pathological 
changes on GABA-ergic 
neurons. 9 months old GK 
rats were treated with clinical 
dosing of Ex-4 for 6 weeks.  
The animals were deeply 
anesthetized; blood was collected through cardiac puncture and then perfused transcardially 
with saline followed by paraformaldehyde (4 %, ice cold).  
 
3.1.4 Study 4 
A clinical study on patients that had 
undergone rtPA treatment for 
ischemic stroke and had no known 
diabetes. The participants underwent 
a 75 g OGTT at day 2-4 after 
admission. They were then invited 
back for a follow-up OGTT 3 months 
later. Functional outcome was scored 
at the second visit.  
The study was open for inclusion between January 2014 and January 2017. A total of 379 
patients were treated with rtPA at the hospital during this time period. A research nurse 
consecutively screened patients for eligibility. The recruited population is a subset of the total 
rtPA treated population at Södersjukhuset that had no pharyngeal palsy, as swallowing was 
necessary for the OGTT, and needed to be in a condition that allowed informed consent. This 
makes the subpopulation slightly younger and with somewhat lower NIHSS-scores compared 
to the total rtPA treated population. Patients who at discharge from hospital or at the three-
month follow up were diagnosed with a condition other than stroke (stroke mimic) were 
excluded from the study. A total of 59 patients were included. 
Figure 8. Outline of study events in Study 4. rtPA: 
recombinant tissue plasmin activator, OGTT: oral 
glucose tolerance test, d: days, m: months.  
Figure 7. Experimental design Study 3. GK: Goto-
Kakizaki rats, Ex-4: exendin-4, ip.: intraperitoneal, 
b.i.d.: twice daily, m: months, w: weeks.  
 26 
As a comparator, a group of healthy individuals were recruited by advertisement. They 
underwent a single OGTT and anthropometric data was collected.  
 
3.1.5 Study 5 
A randomized clinical trial performed in the pre-hospital arena in patients with acute 
suspected stroke. Four ambulance stations with Södersjukhuset as primary target hospital 
participated (Farsta, Nacka, Värmdö and Södermalm). Ambulance nurses were individually 
trained and delegated to include patients and to receive the informed consent of the included 
patients. A total of 109 ambulance nurses were trained in the study.  
The study was registered prior to first randomization on the EU clinical trials site: 
www.clinicaltrialsregister.eu registered as “PROLOGUES - Prehospital lowering of glucose 
in Stroke” (Identifier 2011-002780-16). 
The patients were screened, included and randomized in the ambulance and were followed 
for 24 hours. If randomized to exenatide, treatment was initiated in the ambulance. During the 
first 4 hours glucose was checked every hour, and thereafter every 4 hours.  
The study was open for inclusion between May 2013 and May 2018. Inclusion and exclusion 
criteria were chosen so they were possible to determine in a stressful prehospital 
environment. Inclusion criteria were: ≥ 1 point on the FAST-test (Face Arm Speech Time), 
symptoms of stroke with a duration less than 6 hours, capillary plasma glucose 8-15 mmol/L, 
age ≥ 18 and signed informed consent. Exclusion criteria were: T1D, antidiabetic treatment 
other than metformin, pregnancy, cirrhotic liver disease, regular hemo- or peritoneal dialysis, 
GCS < 4 or GCS verbal < 5, signs of pharyngeal palsy or previously known dementia.  
Due to slow recruitment two changes to the protocol were made regarding the 
inclusion/exclusion criteria. The interval for glucose was widened from 10-15 mmol/L in the 
beginning to 8-15 mmol/L and a change was made to also allow for metformin treated 
patients to be included.  
3.2 ANIMAL MODELS OF DIABETES (STUDY 1 AND 3) 
In this thesis two animal models of diabetes have been used. 
3.2.1 High fat diet (Study 1) 
The use of high fat diet (HFD), with 60 % of energy from fat, is a way of inducing a T2D-like 
phenotype in mice. It also induces concomitant conditions seen in human T2D such as 
nonalcoholic fatty liver disease (NAFLD) and chronic inflammation (216). It takes months to 
induce diabetes in this way and the result is mild hyperglycemia. This is, however, a strength 
when modeling human T2D that usually also takes time to develop. When studying a disease 
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such as stroke that most often occurs in aged humans, a model of aged animal is better suited 
to produce transferable results.  
HFD was started at the age of 2 months and was continued for 12 months to induce diabetes. 
Fasting glucose in the HFD group was 11±3 mmol/L.  
Figure 9. Effect of HFD on mice in Study 1. Body weight (A), fasting plasma glucose (B) or 
plasma glucose in the fed state at time of MCAO (C). HFD: 14 months old mice treated with 
high fat diet for 12 m, normal: 2 months old healthy mice. Bars indicate SEM, **** denotes 
p<0.0001. Adapted and reproduced under creative commons attribution license (CC BY 4.0) 
from DOI: 10.1371/journal.pone.0103114 
3.2.2 Goto-Kakizaki rats (study 3) 
The Goto-Kakizaki-rat (GK-rat) is a non-obese model of T2D. It was developed by selective 
inbreeding of Wistar rats, and is consequently a derivative of the Wistar rat strain (33). They 
spontaneously develop hyperglycemia. With increasing age, they progress to insulinopenia as 
well. The GK-rats develop β-cell dysfunction similar to human T2D patients (217). They also 
develop common T2D complications seen in T2D patients (218).  
The young GK rats (3 months) had slight fasting hyperglycemia, approximately 9 mmol/L 
compared to 6 mmol/L for the Wistars. In the 13 months old GK rats, the fasting 
hyperglycemia was approximately 18 mmol/L. The plasma insulin levels were lower in the 
  
Figure 10. Glycemia and development of insulinopenia in the GK rats compared to Wistar 
rats. 3 and 13 months old. Fasted blood glucose (A) and fed plasma insulin (B). Bars 
indicate SEM. *, **, *** and **** denote p<0.05, 0.01, 0.001 and 0.0001 respectively. ©IOS 
Press, adapted and reprinted from DOI: 10.3233/JAD-131958 
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GK rats compared to the Wistars. At 3 
months the insulin level was 
approximately 2 μg/L in the GK-rats 
compared with 4 μg/L for the Wistars.  
In the sub-study with Ex-4 treatment, the 
fasting glucose levels in GK rats were 
approximately 10 vs. 6 mmol/L for the 
control group and Ex-4 treated group 
respectively.  
 
 
 
 
3.3 TRANSIENT MIDDLE CEREBRAL ARTERY OCCLUSION (STUDY 1 AND 2) 
Middle cerebral artery occlusion (MCAO) is a technique to 
induce a focal ischemic stroke involving the striatum and 
cortex through occlusion and reperfusion that results in an 
ischemic infarction. 
In brief, this is how the procedure is done: After induction of 
anesthesia the carotid arteries on the left side are exposed. 
The external carotid artery is ligated and through a small 
incision in the external carotid artery a monofilament suture 
coated with silicone is inserted into the internal carotid artery. 
It is advanced to the point of resistance were it blocks the 
origin of the middle cerebral artery. After the filament is 
positioned the wound is closed and anesthesia stopped 
allowing the animal to wake. After 30 minutes of occlusion 
time, anesthesia is restarted and the filament removed again. 
Throughout the procedure and ischemic period, body 
temperature is maintained between 36-38 °C by a heating 
lamp. After the procedure the animals are transferred to a 
heated box where they are kept for two hours until they 
regain full consciousness. The surgeon performing the 
procedure is blinded to treatment allocation.  
  
 
Figure 11. Effect of exendin-4 (Ex-4) on fasting 
blood glucose (A) and fed serum insulin (B) in 
the 9 months old GK rats. Bars indicate SEM. * 
and **** denote p=<0.05 and 0.0001 
respectively. Adapted and reproduced under 
creative commons attribution license (CC BY 
3.0) from DOI: 10.18632/oncotarget.6823.  
 
Figure 12. Hemisphere of 
rodent brain with structures 
Striatum and Cortex indicated. 
Reproduced and adapted 
under the Creative Commons 
Attribution License 4.0 (CC 
BY 4.0) from 
DOI: 10.1042/BSR20160437 
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Figure 13. Schematic picture of MCAO. A rodent brain seen from below. A monofilament (blue) is 
introduced through the internal carotid artery on the left side and blocks the middle cerebral artery, 
thereby inducing an ischemic stroke.  
3.4 IMMUNOHISTOCHEMISTRY (STUDY 1-3) 
3.4.1 Tissue preparation 
The animals intended for immunohistochemistry were deeply anesthetized and perfused 
transcardially with saline followed by paraformaldehyde (4 %, ice cold). The brains were 
extracted and post-fixed over night in 4 % paraformaldehyde at 4 °C. They were then 
transferred to a solution of sucrose (20 %) in phosphate buffer until they sank. The brains 
were then cryo-sectioned in 40 μm thick slices with a sliding microtome.  
For immunohistochemistry (IHC) the slices were then stained as free-floating sections. A 
general description of procedure follows below. Different markers were detected by use of 
various primary antibodies, see below.  
1. The sections were rinsed three times in phosphate buffer solution (PBS).  
2. The sections were quenched with H2O2 (3 %) in methanol (10 %) to block 
endogenous peroxidase activity.  
3. The sections were rinsed PBS three times. 
4. Blocking with serum from the animal species of the secondary antibody in T-PBS 
(PBS with the detergent Triton X-100). This is to reduce background staining and to 
increase membrane permeability.  
5. Incubation with primary antibody in normal serum, typically over night.  
6. Washing three times in T-PBS.  
7. Incubation with Biotinylated secondary antibody against the species of the primary 
antibody for 2 hours (1:200, Vector Laboratories).  
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8. Sections washed three times in T-PBS. 
9. Incubation for 1 h with Avidin-Biotin-Complex-Solution (ABC-Solution). This step 
produces large complexes of avidin-biotin bound to the secondary antibodies. The 
enzyme horseradish peroxidase is bound to the complexes.  
10. Sections washed 3 times in PBS.  
11. Sections incubated with DAB/H2O2 solution for approximately 2-5 minutes until 
color develops. DAB (3,3’-diaminobenzidine) is a substrate for HRP and produces a 
brownish color.  
12. Sections washed 3 times.  
13. Mounting of sections on glass 
14. Sections were dehydrated by ethanol and Xylene. 
15. Covering with cover glass and xylene based coverslip medium.  
3.4.2 Histology markers 
3.4.2.1 NeuN (Study 1 and 2) 
Neuronal Nuclei (NeuN) is a neuron specific marker. Antibodies against NeuN stain most 
neuron types and is present in a wide range of species including rodents and humans (219). It 
is the product of the gene Fox-3 and function as a splicing regulator (220). For IHC the 
primary antibody anti-NeuN from Millipore, MA, USA, was used in a concentration of 
1:100.  
3.4.2.2 Cresyl violet (Study 3) 
A basic dye that can be used to stain the Nissle substance in neurons – granules of the 
endoplasmatic reticulum. 0.1 % Cresyl Violet acetate (Sigma-Aldrich) was used. It is a 
general neuron stain that also stains myelin cells. For neuron quantification only cells with 
neuron morphology were counted.  
3.4.2.3 GAD67 (Study 3) 
Glutamic acid decarboxylase-67 (GAD67) is an enzyme responsible for producing the 
inhibitory neurotransmitter GABA (61). It was detected by mouse anti-GAD67 (1:500, 
Merck Millipore), overnight incubation at 4 °C.  
3.4.2.4 Calcium binding proteins (Study 3) 
A subgroup of the regulatory interneurons are characterized by the presence of calcium 
binding proteins (CaBP), Calbindin-28kD, Parvalbumin and Calretinin(63). They were 
detected by following primary antibodies: rabbit anti-Calbindin-28kD (1:1500, Abcam), 
rabbit anti-Parvalbumin (1:1500, Abcam) and rabbit anti-Calretinin (1:1500, Vector 
Laboratories).  
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3.5 QUANTITATIVE ANALYSIS OF HISTOLOGIC SAMPLES (STUDY 1-3) 
Histologic evaluation was performed in a computer aided manner using the software 
NewCast (Visiopharm, Hoersholm, Denmark) connected to an Olympus BX51 
epifluorescent/light microscope. The number of cells, cell volume and stroke volume was 
evaluated in a blinded manner.  
The cryo-sectioning of the brains was made with serial cutting. This means that each cut 
brain slice was binned serially, resulting in for example 10 sets of slices (10 bins) with an 
offset of the cut thickness, 40 µm, between each set. Slice 1, 11, 21 and so forth would go in 
the first bin. Slice 2, 12, 22 and so forth would go in the second bin. This number of series 
that was cut creates a Section Fraction, (SF). 
Figure 14. Representative photograph taken with light microscope. NeuN immunostained brain 
section of stroke damaged mouse brain (MCAO). Black line delineate area of volume measurement 
(stroke size) Withe line delineate area of reduced cell density post MCAO. Dashed line indicates area of 
quantification. Reproduced under creative commons attribution license (CC BY 4.0) from DOI: 
10.1371/journal.pone.0103114.  
 
3.5.1 Stroke volume measurement 
By use of the software, the area of undamaged brain tissue in the ipsilateral hemisphere was 
measured in the brain sections containing stroke. In the same tissue sections, the areas of the 
contralateral hemispheres were measured. Stroke area was calculated by subtracting the 
measured area in the ipsilateral hemisphere from the contralateral area. Each section was cut 
40 µm thick and by knowledge of the binning, of sections during cutting [Section Fraction 
(SF)] volume can be calculated from the area measurements.  
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3.5.2 Cell number 
The optical fractionator method was used for cell number counting (221, 222). The area of 
interest for quantification is outlined in a computer software on all sections of interest. 
Counting then takes place within a counting frame that is moved at regular intervals (steps) 
over the entire delineated area with a random starting point. The counting frame is a virtual 
computer-added frame that is superimposed on the image by the software; cells within it are 
counted and a set of counting rules decide which cells touching any of the frame borders are 
counted. The step length is chosen so that on average 100-200 cells are counted. The total 
delineated area divided by the number of steps gives a step area. Step area divided by the area 
of the counting frame gives area fraction, (AF). The total number of cells (N) within the area 
of quantification is then calculated by the fractionator formula.  
Formula for estimation: N = n x SF x AF  
N = estimated total number of cells.  
n = counted number of cells 
SF = Section Fraction – number of series that was cut 
AF = Area fraction – step area/frame area  
For a cell density measure, total number of cells was estimated within sampled volume and 
then normalized on standardized unit, e.g. per mm3. Total volume of the structure of interest 
was measured in the same way stroke volume was measured.  
The counting was set up so that the same area was counted within the respective study; 
position relative to Bregma or midline determined by appearance of brain structures such as 
the striatum.  
3.5.3 Cell volume quantification 
The nucleator technique was used (223). The area of interest for volume measurement of cell 
volume was delineated. A counting frame was moved in a stepwise manner over the area and 
measurements were made on the cells within the counting frame. The measurement was then 
performed on cells that fell within the frame by clicking at the approximate center of each cell 
and measuring the distance to the cell boundary along random (computer generated) axes 
projecting out from the center. The software then estimates the volume of each cell using the 
nucleator principle. Between 100-200 cells were measured for each individual animal.  
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3.6 INFLAMMATION STUDIES (STUDY 1 AND 3) 
3.6.1 Study 1  
One of the sub-studies aimed to determine the effect of Ex-4 on post stroke inflammation. 
During the sacrifice the animals were transcardially perfused with saline (0.9 %, ice cold), 
brains divided along the midline (to separate stroke from non-stroke side) and then snap-
frozen in dry ice. The frozen brain samples were then homogenized with cold RNAse free 
PBS. Gene expression of pro-inflammatory cytokines was then analyzed using real-time 
PCR.  
The effect of Ex-4 on cytokine levels in microglia cell cultures was also studied. Whole 
brains of young mice (day 2-3 after birth) were homogenized and microglia cells cultured and 
enriched. They were then stimulated with lipopolysaccharide (LPS) (10 ng/mL, List 
Biological Laboratories Inc., Cambell, CA) with or without Ex-4 (10 nmol/L). Cytokine 
levels were measured with Bio-Plex Pro Assay (Bio-Rad Laboratories, Inc., CA).  
3.6.2 Study 3 
In the sub-study with 6 weeks of treatment with Ex-4 or vehicle in GK-rats, serum cytokines 
(IL-1β, MCP-1, IL-6, IL-10 and TNF-α) was measured with the Bio-Plex Multiple Cytokine 
Assay (Bio-Rad Laboratories, Inc., CA).  
3.7 GLP-1 RECEPTOR KNOCKOUT MODEL  
An experimental model with a null-mutation in the gene for the GLP-1 receptor (GLP-1 -/-) 
was used in Study 2 to determine if the neuroprotective effect from DPP-4 inhibitors is 
mediated through the GLP-1 receptor. These mice develop normally and have normal feeding 
behavior, but develop higher glucose levels during a glucose challenge and also have 
somewhat higher fasting glucose (215).  
3.8 DPP-4 ACTIVITY (STUDY 2) 
To measure the effect of linagliptin treatment on DPP-4 activity in the acute vs. chronic 
linagliptin treatment, study plasma was collected from the mice at sacrifice. The activity was 
measured by fluorescence assay at Boehringer Ingelheim Pharma GmbH & Co (224). The 
activity levels were then normalized to the level in vehicle treated mice.  
The DPP-4 activity in the brain itself was established by extraction and freezing of the brains 
immediately after sacrifice. The frozen brains were homogenized and DPP-4 activity 
established in the same way as described above.  
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3.9 OGTT (STUDY 4) 
On hospital day 2-4 a 75 g fasting oral glucose tolerance test was performed. Venous samples 
were drawn at 0, 60, 90 and 120 minutes. Plasma was separated and frozen at -70 °C for 
batch analysis.  
3.9.1 Glucose analysis 
Glucose during the OGTT was measured as plasma glucose by the HemoCue 201+ system 
(HemoCue AB, Ängelholm, Sweden).  
3.10 INSULIN AND INSULIN RESISTANCE (STUDY 4) 
Plasma insulin was measured as batch analysis from frozen samples at the Karolinska 
University Laboratory by electrochemiluminescence.  
3.10.1 Cederholm Insulin Resistance Index  
To estimate the insulin resistance, we used the Cederholm Insulin Resistance Index (Ceder-
IR) (225). This index is a stronger predictor of cardiovascular disease than other indices, e.g. 
HOMA-IR (225, 226).  
The Ceder-IR is defined as 100 divided by Cederholm sensitivity index. Insulin resistance 
and sensitivity index is calculated by: 
 
𝐶𝑒𝑑𝑒𝑟– 𝐼𝑅 =  100𝐶𝑒𝑑𝑒𝑟ℎ𝑜𝑙𝑚 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 
 
𝐶𝑒𝑑𝑒𝑟ℎ𝑜𝑙𝑚 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 =  𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑢𝑝𝑡𝑎𝑘𝑒 𝑟𝑎𝑡𝑒𝑚𝑒𝑎𝑛 𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒log𝑚𝑒𝑎𝑛 𝑖𝑛𝑠𝑢𝑙𝑖𝑛  
 
Glucose uptake rate was defined as (in a 75 g OGTT): [75,000 (mg)/120 (min)] + [[0-min 
glucose (mmol/L) – 120-min glucose (mmol/L)] x 0.19 x body weight (kg) x 180/120 (min)]. 
0.19 x body weight calculates glucose space and 180 is the conversion factor of glucose 
between mmol/L to mg/L. Mean blood glucose was defined as glucose at 0 minutes + 120 
minutes divided by 2. Log mean insulin was defined as log (Insulin at 0 minutes + 120 
minutes divided by 2). Described in detail in the work by Zethelius and Cederholm (225).  
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3.11 GLP-1 ANALYSIS 
GLP-1 in the linagliptin study (Study 2) was measured as active GLP-1 with a commercially 
available ELISA kit (K150JWC-1, Mesoscale, Gaithersburg, USA). This kit detects both the 
GLP-1 (7-36)-amide and the 7-37 form.  
In Study 4 GLP-1 was measured as total GLP-1 by batch analysis of the frozen samples by 
radioimmunoassay using the antiserum 89390. It detects both the active form of GLP-1 (7-36 
amide) and the primary metabolite (9-36 amide). It detects but less than 0.1 % of the GLP-1 
7-7 form, glucagon, gastric inhibitory peptide (GIP) and vasoactive intestinal peptide (VIP) 
(227). Detection threshold was 1 pmol/L and the coefficient of variation was < 6 %. 
3.12 CLINICAL INVESTIGATIONS 
3.12.1 FAST/CPSS 
In study 5, a likely diagnosis of suspected stroke was made using the clinical investigation 
tool Face-, Arm-, Speech-test (FAST). A stroke is suspected by the presence of any of the 
acronym components: asymmetry or impaired movement of one side of the face, weakness in 
one arm or speech impairment. FAST is a development of the Cincinnati Prehospital Stroke 
Scale (CPSS) but instead of using a pre-specified term to determine speech abnormality (The 
patient repeats “The sky is blue in Cincinnati” or the Swedish equivalent “Det är vackert 
väder idag”), speech abnormality is adjudicated in the normal interaction with the patient. 
The CPSS has good reproducibility and validity (228).  
The sensitivity and specificity for detection of stroke is 66 % and 88 % respectively with one 
element of the scale being abnormal (228).  
In the study, we used one point on the FAST scale in combination with clinical suspicion of 
stroke in the opinion of the ambulance nurse as a requirement for inclusion.  
3.12.2 NIHSS 
The National Institutes of Health Stroke Scale (NIHSS) is clinical examination scale that can 
be used to rate the severity of a stroke (229). The scale is comprised of motor function tests, 
sensory evaluations, level of consciousness, neglect and language ability. Higher scores 
indicate a larger stroke with more severe functional deficits. The score has been used in 
numerous stroke trials to assess stroke severity, including the pivotal rtPA trials. NIHSS has 
been shown to strongly predict the outcome of a stroke with the likelihood of excellent 
outcome at three months dropping by 17 percent for each additional point on the NIHSS 
(230).  
In Study 4, NIHSS was used to compensate for initial stroke severity when examining the 
relationship between GLP-1 and three-month outcome. In Study 5, NIHSS was included as 
baseline characteristic.  
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3.12.3 mRS 
Modified Rankin Scale (mRS) is a stroke outcome scale. It ranges from 0 (no symptoms) to 5 
(severe disability, in need of constant nursing care) (231). Sometimes a grade 6 (dead), is 
added. In Study 4 favourable outcome after the stroke was defined as mRS 0-1 (232).  
 
mRS Definition 
0 No symptoms. 
1 No significant disability. Able to carry out all usual activities, despite some symptoms. 
2 
 
Slight disability. Able to look after own affairs without assistance, but unable to carry 
out all previous activities. 
3 Moderate disability. Requires some help, but able to walk unassisted. 
4 Moderately severe disability. Unable to attend to own bodily needs without 
assistance, and unable to walk unassisted. 
5 Severe disability. Requires constant nursing care and attention, bedridden, 
incontinent. 
 
Table 4. Description of the modified rankin scale (mRS). Sometimes a 6 is added: dead.  
 
3.13 STATISTICAL METHODS (ALL PAPERS) 
In Study 1, Student’s unpaired t-test was used for assessing differences in inflammatory 
markers in microglia cultures. One-way analysis of variance (ANOVA) with Tukey’s 
multiple comparison correction was used to compare the stroke volume estimates and NeuN 
counts. Inflammatory markers in the in-vivo (sub-study 4) part of Study 1 were compared 
with Kruskal-Wallis one-way analysis of variance followed by Dunn’s multiple comparisons 
test.  
In the animal stroke study with linagliptin (Study 2), Student’s unpaired test was used.  
In the interneuron Study (Study 3), two-way ANOVA with Tukey’s multiple comparisons 
correction was used to analyze differences and allow for interaction between age and 
diabetes. Cytokine levels were analyzed by Student’s unpaired t-test.  
In the clinical OGTT study (study 4), a Univariate General Linear Model (GLM) was used to 
compare fasting levels of GLP-1, insulin and glucose between patients and controls. For 
comparison of the fasting GLP-1 and insulin measures between the acute phase and the three-
month follow-up the non-parametric test Wilcoxon Signed Ranks Test was employed. 
Glucose and insulin were analyzed by two-way ANOVA. Huynh-Feldt correction was used 
to adjust for sphericity violation. Logistic regression was used to determine the association 
between GLP-1 and stroke outcome. In this analysis, mRS was grouped as favorable if mRS 
was 0-1 or unfavorable if mRS ≥ 2, all other variables of non-binary nature was treated as 
continuous.  
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In the expanded analyses of GLP-1 and glucose (using data from 0, 30, 90 and 120 minutes) 
between the stroke patients and the healthy controls during the OGTT, a Univariate General 
Linear Model was used in the same way as the analysis of only fasting levels, but with 
repeated measurements. This was not presented in the paper in Cardiovascular Diabetology. 
When comparing GLP-1 levels between the acute phase and the three-month follow up two-
way ANOVA was used instead of the Wilcoxon Signed Ranks Test.  
In the study examining exenatide in the ambulance (Study 5), analysis of p-glucose at 4 h and 
analyses of the AUC of capillary glucose during the first 4 h and 24 hours were made with 
the non-parametric Mann-Whitney U-test as primary analysis. A complementary analysis was 
made with linear regression to allow for adjustments (age, sex and BMI).  
In Study 1-3 GraphPad Prism v. 5 & 6 (GraphPad Software, CA, USA) were used for the 
statistical analyses. In Study 4-5 SPSS v23.0.0.3 (IBM Corp, Armonk, NY, USA).   
3.13.1 Missing data 
Overall, the level of missing data was very low. There were no missing data points from the 
animal studies. In Study 4, one GLP-1 measurement was missing from one person in the 
control group. Since ANOVA requires complete cases for analysis, that individual was 
excluded in those analyses. In Study 5, data on venous glucose measurements at 4 hours was 
missing for three individuals and for some of the capillary glucose measurements. This was 
handled with different forms of sensitivity analyses and with replacement of capillary values 
for the missing venous as outlined in the manuscript.  
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4 ETHICAL CONSIDERATIONS 
Study 1-3 were performed in accordance with the “Guide for Care and Use of Laboratory 
Animals” published by the National Institutes of Health in U.S. These studies were approved 
by the animal research ethical board at the Agricultural department and the local ethics board 
for animal research (“Stockholms södra djurförsöksetiska nämnd”). When designing the 
studies we used the principle of 3 R: Replace, Reduce and Refine. It was not possible to 
replace the animals with other methods as we studied complex interactions in the brain after 
stroke, which is not possible to study in, for example, a cell culture. From previous studies, 
both our own and performed by others, we had knowledge of the group size needed to detect 
meaningful differences. We could thereby keep the number of animals in each experimental 
group low and did not need to overuse the number of animals. The animals could furthermore 
be used in multiple experiments. The brains were extracted and serially cut (binned) ensuring 
up to 10 and equivalent sets of sections that could be stained with different markers. The 
research group had furthermore several scientific questions regarding different parts of the 
brain that could be examined in the same sections, reducing the need for sacrificing more 
animals. The type of information and knowledge gained form the animal studies is not 
possible to gather in any other way, neither in cell cultures nor in humans. I therefore 
consider the performed research ethical.  
The clinical studies (Study 4-5) were performed in accordance with the Declaration of 
Helsinki and were approved by the regional ethical board at Karolinska Institutet (Study 4) or 
the Swedish Central Ethics board (Study 5). Informed consent was obtained from all 
participants.  
In Study 4, the patients were all without known diabetes, but had suffered a stroke. Diabetes 
is a well-known risk factor for stroke and OGTT is a standard procedure to establish if 
someone has diabetes or impaired glucose tolerance. The procedure they went through was 
therefore something that would (at least should) have been undertaken regardless of if they 
participated in the study or not. The extra blood samples taken during the OGTT were taken 
through a peripheral cannula and not through repeated punctures, reducing suffering and pain. 
The volume of blood, about 30 mL, is not considered harmful. The risk to which the healthy 
controls were exposed was also very limited and they had the benefit of having their 
metabolic status (glucose tolerance) measured as a form of check up.  
Study 5 was more complex from an ethical viewpoint. Stressed patients with potential acute 
brain injury were asked to participate in a clinical trial. The problem of including patients in 
the pre-hospital arena is further elaborated on in the discussion part. The drug they were 
exposed to, exenatide, was however already an approved drug for the treatment of diabetes 
with known properties and side effects. We also made some adaptions of the protocol from 
the beginning to minimize potential harm to the study subjects. Our hypothesis was that 
hyperglycemia is harmful in the acute phase. We therefore did not want to include patients 
with very pronounced hyperglycemia in a study with a drug not previously tested in this 
setting. We consequently set a threshold of 15 mmol/L in glucose as a maximum for 
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inclusion. It is not possible to perform this type of study in alternative models such as animals 
or cell cultures. Additionally, our hypothesis was that GLP-1RA treatment is beneficial with 
glucose lowering capacity without concomitant risk of hypoglycemia. This was of potential 
benefit to the patients and the risk they were exposed to was limited so we found the research 
to be reasonable and could be motivated from an ethical point of view.  
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5 RESULTS 
5.1 STUDY 1 EXENDIN-4 IN MICE 
In this study we aimed to determine the neuroprotective efficacy of GLP-1RA Ex-4 given 
after stroke and to study its effect on the inflammatory response. 
In short, our results showed that Ex-4 given after stroke was neuroprotective, both in young 
animals and old diabetic animals. Additionally, Ex-4 shifted the inflammatory response to a 
more reparative response, M2.  
5.1.1 Exendin-4 reduces effect of stroke in dose- and time-dependent 
manner.  
Administration of Ex-4 immediately after MCAO-induced stroke resulted in an increase in 
the number of NeuN-positive neurons in the striatum of 2-month-old mice. In sub-study 1 (5 
µg/kg bolus) the increased neuronal number was detected if bolus was given 1.5 hours after 
MCAO (p<0.05), but lost if given after 3 hours. In sub-study 2 (50 µg/kg bolus) there was an 
increase in NeuN-positive neurons both at treatment initiation at 1.5 (p<0.001) and 3 hours 
(p<0.05). No effect was seen if treatment was started 4.5 hours after stroke. No effect was 
seen in the cortex and there was no difference in stroke volume. Figure 15. 
Figure 15. Neuroprotective effect of Exendin-4 in the striatum after stroke in normal adult 
mice. Time point indicates how long after MCAO Ex-4 treatment was initiated. Dashed line 
show number of neurons on contralateral side. Ex-4: exendin-4, PBS: Phosphate buffer 
solution (placebo). Bars indicate SEM, *, **, and *** represent p<0.05, p<0.01 and p<0.001 
respectively. Adapted and reproduced under creative commons attribution license (CC BY 
4.0) from DOI: 10.1371/journal.pone.0103114 
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5.1.2 Exendin-4 is neuroprotective in aged diabetic and obese mice 
In 14 months old and diabetic mice, treatment with Ex-4 was neuroprotective in MCAO 
induced stroke, both when initiated 1.5 and 3 hours post MCAO (p<0.05 and p<0.05). In 
contrast to the young animals, the effect was seen in the cortex but not in the striatum.  
5.1.3 Exendin-4 treatment affect microglia phenotype  
Ex-4 treatment initiated 1.5 hours post MCAO did not affect the inflammatory response 
pattern of inflammatory markers such as, MCP-1, IL-1β and TNF-α as measured by real-time 
PCR. However, the microglia phenotype response pattern was shifted towards a more 
reparative, M2 response, with up-regulation of gene expression of CD206, ARG1 and YM1/2 
in the Ex-4 treated animals.  
5.2 STUDY 2 LINAGLIPTIN IN MICE 
Here the goal was to determine the neuroprotective efficacy of the DPP-4i linagliptin given 
after stroke and to establish if the effect was dependent on the GLP-1 receptor.  
In short, our results show that the DPP-4i linagliptin was neuroprotective if it was given 
chronically before and continued after experimental stroke. The study also showed that the 
effect was independent of the GLP-1 receptor.  
In wild type mice there was no difference in the stroke volume or the number of NeuN-
positive neurons when linagliptin was given acute iv. at MCAO. By contrast chronic 
treatment started four weeks before MCAO increased the number of surviving neurons by 
approximately 30 % compared to vehicle, p=0.003 (Figure 16). The difference in stroke 
volume with approximately 40 % smaller stroke volume in linagliptin treated animals was not 
significant, p=0.06.  
Figure 16. Neuroprotective effect of linagliptin in stroke. Number of NeuN-positive neurons in 
the striatum and cortex. Linagliptin was given either acutely after MCAO or chronically for 4 
weeks before MCAO. Bars indicate standard deviation. ** represent p<0.01. © 2016 John 
Wiley and Sons, reproduced and adapted with permission from DOI: 10.1111/dom.12641.  
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DPP-4 activity was significantly reduced in both the acute treatment and chronic treatment 
groups, with GLP-1 levels increased approximately 10 times, p<0.0001.  
In the GLP-1 receptor knockout mice, linagliptin treated animals had an approximately 55 % 
reduction in stroke volume compared to vehicle treated, p=0.008. The GLP-1RA Ex-4 had no 
effect in the GLP-1 receptor knockout animals. Figure 17. 
 
Figure 17. Linagliptin induced neuroprotection is GLP-1R independent. GLP-1R -/- (KO) and 
wild type (WT) mice treated chronically for 4 weeks with vehicle/linagliptin p.o. or vehicle/Ex-
4 before MCAO. Treatment continued 3 weeks after MCAO. A: Ischemic volume 
quantifications in KO mice after chronic linagliptin treatment. B, C: Ischemic volume 
quantification in WT and KO mice after chronic Ex-4 treatment. Bars indicate standard 
deviation. * denote p<0.05, ** denote p<0.01. © 2019 John Wiley and Sons, reproduced with 
permission from DOI: 10.1111/dom.12641. 
 
5.3 STUDY 3 GABA-ERGIC NEURONS IN RATS 
The aim was to establish if, and how, aging and T2D affect cortical and striatal GABA-ergic 
neurons. The aim was also to determine if potential changes could be counteracted by 
treatment with the GLP-1RA Ex-4.  
In short, our results showed that diabetes negatively affects GABA-ergic neurons in aging 
rats and that the effect is partially counteracted by Ex-4.  
The overall density of neurons in the striatum and cortex was not different in the Wistar or 
GK-strains, neither at 3 nor 13 months, as tested with Cresyl Violet staining.  
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Figure 18. The effect of aging in type 2 diabetes in Wistar and GK-rats. GAD67 positive cells 
in the cortex and striatum. Bars indicate standard deviation. Two-way ANOVA was used to 
test group difference and the interaction between strain and age. 3m: 3 months old, 13m: 13 
months old. * represent p<0.05, ### represent p<0.001 for interaction. Adapted and 
reproduced under creative commons attribution license (CC BY 4.0) from DOI: 
10.1042/BSR20160437.  
The study investigated the interaction effect of aging and diabetes on GABA-ergic 
interneurons. There was an increase in striatal GAD67-positive neurons in the old non-
diabetic Wistar rats (p<0.05) vs. a reduction in the old diabetic GK-rats (p<0.05), p<0.001 for 
interaction. This interaction was not present in the cortex where neither strain had any 
difference in the neuronal density in the old vs. young animals. See Figure 18. 
Three specific subtypes of interneurons were also stained for, Calbindin (CB), Calretinin 
(CR) and Parvalbumin (PV). There was a large reduction in the number of CB-positive cells 
in the 13-month-old compared to the 3-month-old GK rats, with around 45 % reduction in the 
cortex (p<0.0001) and 80 % reduction in the striatum (p<0.001). There was a similar trend in 
the striatum for CR, but it did not reach statistical significance after correction for multiple 
testing.  
5.3.1 Exendin-4 partially counteracts T2D changes in aging 
In sub-study 2, Ex-4 treatment for 6 weeks before sacrifice gave a 90 % increase in the 
number of CB-positive cells in the striatum (p<0.01). No difference was detected in the 
cortex. For GAD67, CR and PV no difference was found.  
 
5.4 STUDY 4 OGTT IN rtPA TREATED STROKE PATIENTS 
In this clinical study, the aim was to determine if endogenous GLP-1 secretion is altered in 
the acute phase of stroke and if the GLP-1 levels in acute stroke are correlated to functional 
outcome of the stroke.  
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In summary, the results show a higher GLP-1 level in patients that recently suffered an 
ischemic stroke compared to healthy controls. There was no association between the GLP-1 
level in the acute phase of stroke and functional outcome.  
A total of 379 patients were treated with rtPA for ischemic stroke at Södersjukhuset, 
Stockholm, Sweden between January 2014 and January 2017. Patients were consecutively 
screened by a research nurse for eligibility. 59 patients were included in the study and 
underwent the first OGTT. 51 underwent the second OGTT. 7 were lost to follow-up or 
declined a second OGTT and 1 patient died during follow-up. A control group of healthy 
volunteers was included for comparison (n=27). Characteristics of the stroke and control 
groups are shown in Table 5. As all patients treated with rtPA at Södersjukhuset are included 
in a quality of care registry. Characteristics of the entire rtPA treated cohort are included for 
comparison.  
The included patients compared to the total rtPA treated cohort were younger (70.6 vs. 74.5 
years), comprised of more males (66 vs. 51 %) and had lower NIHSS scores (4 vs. 6). 
Compared to the stroke patients, the group of healthy controls that underwent OGTT was 
younger (44.6 vs. 70.6 years), lower BMI (22.7 vs. 26.2) and had fewer men (40.7 vs. 66.1).  
 
Characteristic OGTT in Stroke 
(n=59) 
OGTT controls 
(n=27) 
Total rtPA cohort 
(n=379) 
Age, years 70.6 (61.5-76.2) 44.6 (27.9-68.3) 74.5 (65.3-83.3) 
Male Sex (%) 66.1 40.7 51.4 
NIHSS before rtPA 4 (3-6) - 6 (3-12.5) 
mRS at discharge 1 (1-3) - 2 (1-4) 
BMI, kg/m2  26.2 (23.4-29.3) 22.7 (21.2-26.0) 24.9 (22.9-28.4) 
eGFR, ml min-1 [1.73m]-2 70 (59-76) - 64 (51-76) 
Admission glucose 
mmol/L 
6.8 (6.0-7.5) - 6.7 (5.9-8.0) 
Hypertension 54 % - 56 % 
Systolic BP, mmHg 154 (140-176) - 157 (140-173) 
Diastolic BP, mmHg 89 (80-98.5) - 83.5 (75-93) 
Atrial fibrillation, n (%) 8 (14 %) - 20 
Current smokers, n (%) 6 (10 %) - 12 
Prev. diabetes, n (%) 0 (0 %) 0 (0 %) 15 
Pathologic OGTT, n (%) 34 (58 %) 3 (11 %) - 
   Normal glucose  
   tolerance 
25 (42 %) 24 (89 %) - 
   Fasting  
   hyperglycemia 
11 (19 %) 1 (4 %) - 
   Impaired glucose  
   tolerance 
31 (53 %) 3 (11 %) - 
   Diabetes 3 (5 %) 0 (0 %) - 
Table 5. Baseline characteristics of the stroke patients, healthy controls and total rtPA treated 
cohort. Values presented as median (IQR) or (%). IQR; interquartile range, NIHSS: National 
Institutes of Health Stroke Scale, mRS: modified Rankin scale, BMI: body mass index, eGFR: 
estimated glomerular filtration rate, BP: blood pressure. Adapted under creative commons 
attribution license (CC BY 4.0) from DOI: 10.1186/s12933-019-0896-z. 
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5.4.1 Patients treated with rtPA for ischemic stroke have higher GLP-1 levels 
During the OGTT performed on day 2-4 in the acute phase of stroke in patients that were 
treated with rtPA for ischemic stroke samples were taken at 0, 60, 90 and 120 minutes. The 
same time-points were sampled in the healthy controls. The stroke patients had higher levels 
of fasting GLP-1 compared to the healthy controls (25.1 vs. 18.0 pmol/L, p=0.004). Figure 
19A. In a univariate GLM model taking all time-points into account the estimated marginal 
means for stroke patients and controls showed a consistent overall difference at 31.1 vs. 26.0 
pmol/L (difference 5.1 pmol/L, 95% CI 1.1 - 9.2 pmol/L; p=0.013), Figure 20. 
There was no evidence of difference in the levels of fasting glucose between the stroke 
patients and the control group (5.3 vs. 5.6 mmol/L, p=0.33) (Figure 19C) or the levels of 
fasting insulin (13.2 vs. 9.8 mU/L, p=0.20) (Figure 19A). The stroke patients did, however, 
develop higher glucose at the end of the OGTT (7.8 vs. 6.1 mmol/L, p<0.001. Figure 19C. 
There was no difference in the fasting GLP-1 levels between the acute phase of stroke and the 
three-month follow up (25.8 vs. 25.6 pmol/L, p=0.80). Neither was there any difference 
between the acute phase and the three-month follow up in a repeated measures two-way 
ANOVA taking all time-points during the OGTT into account with the estimated marginal 
means 31.7 vs. 33.6 pmol/L (difference 1.85 pmol/L 95 % CI, -1.6 – 5.3 pmol/L, p= 0.29), 
Figure 20B.  
Figure 19. Fasting plasma GLP-1 and insulin (A and B) and plasma glucose (C and D) from a 
120 min OGTT. Data is presented as mean values, bars indicate 95 % CI. In panel A and C 
the graphs show means adjusted for sex, age and BMI. Reproduced under creative commons 
attribution license (CC BY 4.0) from DOI: 10.1186/s12933-019-0896-z 
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5.4.2 No association between GLP-1 in the acute phase after stroke and 
outcome 
There was no association between the GLP-1 levels measured in the acute phase after stroke 
and the three-month functional outcome defined as mRS ≥2. This remained unchanged, no 
matter if fasting GLP-1 was used as predictor, or if other measures e.g. AUC of GLP-1 
during the OGTT, was used. The unadjusted results were the same as if adjustment was made 
for NIHSS, sex, age and BMI. Unadjusted OR for unfavorable outcome for fasting GLP-1 as 
predictor was 0.99 (95% CI 0.89-1.10, p=0.85), Table 6.  
 Unadjusted OR  
(95 % CI) 
p-value Adjusted* OR  
(95 % CI) 
p-value 
GLP-1 at 0 minutes 1.03 (0.95-1.12) 0.50 0.99 (0.89-1.10) 0.85 
GLP-1 AUC at 
stroke 
1.01 (0.99-1.03) 0.29 0.99 (0.95-1.02) 0.50 
GLP-1 rise AUC 1.00 (0.99-1.03) 0.44 0.99 (0.96-1.03) 0.60 
GLP-1 max rise 1.00 (0.98-1.03) 0.78 0.98 (0.94-1.02) 0.32 
 
Table 6. Odds ratios (OR) for GLP-1 as predictor for unfavorable outcome *Adjusted for age, 
sex, initial National Institutes of Health Stroke Scale (NIHSS), Cederholm insulin resistance 
index (Ceder-IR) and atrial fibrillation.  
 
Figure 20. Plasma GLP-1 (A and B) and plasma glucose (C and D) during a 120 min OGTT. 
Data is presented as mean values, bars indicate 95 % CI. In panel A and C the lines show 
hypothetical curves during a 120 min OGTT for a male aged 62 years with BMI 25 
(population means). 
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5.5 STUDY 5 EXENATIDE IN AMBULANCE 
A randomized pilot trial with the aim to evaluate overall feasibility of treating hyperglycemia 
starting in the ambulance among patients with suspected stroke.  
In short, the study found no evidence of a glucose lowering effect but the treatment 
administration was feasible without adverse events.  
In total, 19 patients were included between May 2013 and May 2018. The study was stopped 
early due to slow recruitment. 8 were randomized to exenatide. Baseline characteristics are 
found in Table 7. The treated group was slightly younger (71 vs. 80 years) and had higher 
NIHSS-score on admission (median of 4.5 vs. 1).  
Characteristic Control (IQR) Exenatide (IQR) 
Age, years 80 (63-89) 71 (54-82) 
Male sex, n (%) 6 (55 %) 4 (50 %) 
BMI, kg/m2 26.4 (23.2 – 31.7) 27.2 (21.6 – 29.5) 
cP-Glucose, mmol/L 9.6 (9.0-10.8) 9.6 (8.4-10.6) 
vP-Glucose, mmol/L 9.4 (7.9-11.2) 8.8 (6.9-10.9) 
Systolic blood pressure, 
mmHg 
165 (130-190) 150 (124-175) 
Diastolic blood pressure, 
mmHg 
89 (80-100) 80 (76-98) 
Heart rate 88 (72-90) 80 (68-89) 
NIHSS 1 (0-4) 4.5 (1-8) 
Discharge diagnosis   
    Ischemic Stroke, n 9 4 
    Hemorrhagic Stroke, n 0 2 
    Non-Stroke, n 2 2 
Treated with rtPA, n 1 0 
 
Table 7. Baseline characteristics of the included patients in the prehospital exenatide study. 
Data is presented as median with interquartile range unless otherwise specified. 
IQR: interquartile range, BMI: body mass index, cP-Glucose: capillary plasma glucose, 
vP-Glucose: venous plasma glucose, NIHSS: National Institutes of Health Stroke Scale, rtPA: 
recombinant tissue Plasminogen Activator. © 2019 John Wiley and Sons, reproduced and 
adapted with permission from DOI: 10.1111/ane.13166. 
 
5.5.1 Slow recruitment analysis 
The study was stopped early due to slow inclusion after having included 19 of the target 42 
patients. Slow inclusion was identified early in the course of the trial and several attempts to 
address this were made. The inclusion and exclusion criteria were changed after applications 
for amendments to the protocol. At the onset of the trial, for instance, the inclusion criterion 
for glucose was 10-15 mmol/L. This was first expanded to 9-15 mmol/L and finally to 
8-15 mmol/L. Originally, all persons with previously known diabetes were excluded, but later 
changed to previously known diabetes treated with anything other than lifestyle/diet or 
metformin.  
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A recruitment failure analysis was made in 2015 at the largest participating ambulance 
station, responsible for approximately 25 % of ambulance transports to the study hospital and 
50 % of the study ambulances. The first four months of 2015 were analyzed, at which time 
the inclusion range for glucose was 9-15 mmol/L. Among the non-included patients, 143 
dispatches for suspected stroke were made. After ambulance nurse evaluation 69 patients 
remained, and out of these, 13 had the required glucose of 9-15 mmol/L. 11 would have been 
excluded, mainly for problems pertaining to obtaining informed consent. 2 patients were true 
recruitment failures. The initial 13 eligible patients would have been increased to 19 with a 
glucose inclusion range of 8-15 mmol/L. As a result, the inclusion range was expanded after 
an approved protocol amendment.  
5.5.1.1 93 Ambulance Nurses 
The study was required to arrange a personal delegation to each participating ambulance 
nurse to inform the patients and obtain informed consent. This meant that each time a trained 
nurse switched jobs a potential study recruiter was lost. Repeated study trainings were 
arranged in an effort to keep the pool of nurses informed and able to include patients. In total 
93 nurses were trained and individually delegated. Regular informal contacts with the 
participating stations also took place, aside from the trainings, to maintain motivation. ML, as 
study physician, was also available around the clock throughout the study period for 
telephone consultations regarding the study.  
 
5.5.2 Glucose outcome 
There was no evidence of difference in glucose level at 4 hours, the primary glucose 
endpoint. Exenatide treated vs. control group: 7.6 vs. 7.0, p=0.56. A linear regression model 
with adjustment for age, sex and BMI did not alter the result: 7.1 vs. 7.4, p=0.76. 
Complementary analyses to measure glucose exposure as AUC was also performed, but no 
evidence of a difference was found. See Figure 21, p-values denote statistical tests of AUC 0-
4 hours and 0-24 hours. 
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Figure 21. Capillary plasma glucose. P-values in figure represent Mann-Whitney U-test of 
AUC 0-4 h and 0-24 h. Bars indicate standard deviation. © 2019 John Wiley and Sons, 
reproduced permission from DOI: 10.1111/ane.13166. 
 
5.5.3 Adverse events 
Adverse events were recorded throughout the study period. No major adverse events and no 
hypoglycemic episodes were reported. One patient experienced nausea and vomiting, but had 
done so prior to inclusion. This patient suffered from a basilar thrombosis which, rather than 
the treatment, was considered to be the most likely explanation.  
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6 DISCUSSION 
Stroke can be a debilitating disease. Persons with diabetes are at greater risk of suffering an 
ischemic stroke and experience a worse functional outcome. This thesis has focused on how 
to mitigate the effects of ischemic stroke by means of GLP-1-mediated neuroprotection. 
Importantly, the experimental work was performed by using a clinically relevant set-up. This 
facilitates the potential transfer of the findings, and thereby increases the value of scientific 
endeavor through translational research.  
For this purpose, we have studied GLP-1RA treatment given after the onset of stroke, both in 
an experimental animal study (Study 1) and parallel to this, with a similar setup, we 
randomized suspected stroke patients in a clinical trial evaluating prehospital treatment with 
the GLP-1RA exenatide (Study 5). We have also studied if neuroprotection could be achieved 
by means of increasing the endogenous GLP-1 levels through, at the onset of stroke, 
inactivation of the GLP-1-degrading enzyme DPP-4 by the administration of linagliptin 
(Study 2). Furthermore, we tried to find explanations as to why persons with diabetes show 
impaired recovery after stroke by studying a subset of key regulatory neurons in stroke 
recovery: interneurons (Study 3). Additionally, in Study 3, we also evaluated whether 
GLP-1RA treatment could have a positive impact on these cells. Finally, we studied the 
endogenous GLP-1 levels in patients exposed to acute ischemic stroke in comparison to 
healthy individuals and the potential association between endogenous GLP-1 levels and 
functional outcome (Study 4). 
 
6.1 GLP-1 RECEPTOR ACTIVATION IS NEUROPROTECTIVE POST STROKE 
AND TIME DEPENDENT 
In Study 1, we showed that it is possible to achieve neuroprotection in experimental stroke 
through activation of the GLP-1 receptor by giving Ex-4 after the onset of stroke. The effect 
persisted if the treatment initiation was delayed up to 3 hours after the onset of stroke. 
However, the effect was lost at 4.5 hours, highlighting the need for a timely intervention. This 
puts the time-window for effective intervention in the same time-frame as rtPA (233). 
Furthermore, the effect was more pronounced at the earlier time point. To be efficacious, the 
treatment should therefore be started as soon as possible, perhaps already in the ambulance 
en-route to hospital. The treatment effect was not dependent on hyperglycemia/diabetes. This 
is in agreement with surrounding literature, with the majority of neuroprotection trials having 
shown GLP-1RA efficacy in non-diabetic animals, e.g. (188, 190-192, 194-198). This opens 
up for the potential use of these drugs in non-diabetic stroke patients as well.  
Study 1 also demonstrated a dose-dependent relationship of the neuroprotective effect 
strengthening the evidence of a true (causal) effect. The initial bolus doses we used in this 
post-stroke study, 5 µg/kg and 50 µg/kg of Ex-4, were higher than usual clinical dosing of 
0.1 µg/kg twice daily. Our study used, however, the standard clinical dose in the prolonged 
phase (for one week after stroke). Interestingly, the protective effect of exenatide 5 µg/kg and 
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50 µg/kg were similar at the 1.5-hour time-point in our study, but at the 3 hour intervention 
only the high dose was neuroprotective. Noteworthy is also that there is evidence for a 
protective effect of the clinical dose as well, albeit in pre-stroke treatment (189). 
Previous studies in hyperglycemic stroke patients have all used insulin, and failed to show 
benefit from glucose reduction. They were, however, often started 8-12 hours or later after 
stroke onset, see Table 3. This delay before insulin intervention could be an explanation to 
why insulin trials have failed. The shorter time interval, between stroke onset and treatment, 
could be why our GLP-1RA treatment was neuroprotective where insulin failed. 
Furthermore, an additional disadvantage for insulin is its ability to cause hypoglycemia, and 
that it often does (see Table 3), with potential negative effects for a brain already under stress. 
GLP-1RA treatment, on the other hand, does not induce hypoglycemia by itself as the 
glucose lowering effect goes away once euglycemia is reached (96-98). Moreover, since the 
neuroprotective effect of GLP-1RA is not dependent of hyperglycemia or diabetes, regulation 
of glycemia at an earlier time point alone is unlikely the sole explanation of its 
neuroprotective efficacy.  
Many previous studies have used young and healthy animals in the model (190, 192-194). 
This reduces their transferability, since stroke mainly occurs in aged and comorbid patients. 
Our study evaluated the effect not only in young animals but also in aged and obese/diabetic 
animals, induced by HFD. The neuroprotective efficacy was similar in the aged animals as 
well; with neuroprotection up to 3 hours post MCAO. We found, however, a difference in 
where the protective effect occurred. In the young animals the protective effect was shown in 
the striatum, but in the aged and comorbid animals the effect was seen in the cortex. This 
difference is hard to explain with certainty, but could be a consequence of different sensitivity 
to stroke in different areas of the brain with larger strokes resulting in larger penumbra zones. 
Most likely it is in the penumbra that the treatment effect occurs. The ischemic damage was 
more pronounced in the striatum of the young animals compared to the striatum in the aged 
and obese animals. For the cortex, the situation was opposite. Changes in the vascularization 
of the brain have been shown to occur in diabetes (234, 235) and could cause the different 
response to MCAO in old/diabetic and young/healthy animals. Although speculative, this 
could be an explanation. 
 
6.2 THE STRUGGLE WITH INCLUDING STROKE PATIENTS IN A 
PREHOSPITAL CLINICAL TRIAL 
The concept of early intervention being the key to successful neuroprotection was behind the 
clinical randomized trial of exenatide given in the ambulance to hyperglycemic patients with 
suspected stroke (Study 5). This was a study mainly focusing on the overall feasibility of 
early intervention with GLP-1RA in hyperglycemic patients with symptoms of acute stroke.  
The study was powered to detect a 2 mmol/L difference in p-glucose at 4 hours with 42 
patients included, but was stopped after 5 years with 19 included patients. The study found no 
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evidence of that exenatide given in the ambulance results in more rapid normalization in 
plasma glucose, but too few patients were included for a certain conclusion. A main finding 
of the study was in fact the difficulties one faces in including patients in the prehospital 
environment. Any study in humans must be based on informed consent, as described in the 
declaration of Helsinki (236). This ethical concern induces challenges in trials on patients 
with acute stroke. As patients are in a situation of great stress and since stroke is a disease 
with a high prevalence of cognitive impairment (237) and aphasia (238) obtaining an 
informed consent based on complex information is difficult. A further hamper is the stressful 
working conditions for the caregivers in the prehospital setting. Our recruitment failure 
analysis is indicative of the aforementioned obstacles. The main reasons for exclusion of 
otherwise suitable study subjects were related to difficulty obtaining informed consent, such 
as dementia, confusion or reduced level of consciousness. 
Another difficulty was the constant turnover of nurses. The ambulance nurse collected the 
informed consent from the participating patients on individual delegation. Every time a nurse 
left their employment, a new one had to be trained and motivated. We strived to keep 
constant contact with the ambulance stations to ensure that nurses were up to date and able to 
include patients. In total 93 nurses were trained and individually delegated throughout the 
trial. A complication for maintaining this contact is the decentralized structure of the 
ambulance services. The ambulance service is, as a natural consequence of the treat and 
retrieve mission, constantly on the roll. This makes assembling them in one place and time to 
inform them more difficult. Furthermore, introducing new devices (injection syringe for 
exenatide), drugs (exenatide) and study glucose meters that the ambulance nurse had little 
previous knowledge about was another barrier. To support the participating nurses the study 
team offered a study physician (M.L.) constantly on call around the clock throughout the 
study for consultations.  
There were, however, no adverse events or other complications in connection with the 
administration of the study drug in the ambulances and in this regard, the prehospital 
treatment with exenatide could be considered feasible.  
 
6.3 LINAGLIPTIN REQUIRES PRE-TREATMENT BUT NOT GLP-1 
RECEPTORS 
Previous studies have shown that DPP-4i treatment is neuroprotective if given chronically 
before and after stroke in animal experimental models. We therefore aimed to determine the 
neuroprotective efficacy of the DPP-4i linagliptin initiated at stroke, as we had done with the 
GLP-1RA Ex-4. We found no evidence of a neuroprotective effect when linagliptin was 
given acutely at stroke. Effect of chronic treatment before and after stroke was, however, 
shown in Study 2, which is in line with previous DPP-4i studies (115, 201). The efficacy was 
shown in non-diabetic animals, indicating that it was glycemia-independent. Again this is in 
line with previous studies. A very interesting discovery of our study was that the 
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neuroprotective effect is not dependent on the presence of a GLP-1 receptor. In fact, in a 
knockout model deficient of the GLP-1 receptor, the DPP-4i neuroprotective effect was still 
present with chronic linagliptin treatment. On the other hand, treatment with a direct GLP-
1RA (Ex-4) was without effect. This is the first evidence showing that the neuroprotective 
effect of linagliptin is mediated through alternate mechanisms, apart from elevation of 
endogenous GLP-1, at least in part. 
DPP-4 is not a substrate specific degradation enzyme, with several other peptides apart from 
GLP-1 being degraded by it, including: SDF1α, GIP and PACAP (107, 108). These peptides 
have been shown to be neuroprotective (209, 239, 240). Inhibition of DPP-4 leads to modest 
elevations of all its substrates. A combination of several peptides could be responsible for the 
neuroprotective efficacy of DPP-4i, an effect not dependent on diabetes. An additional study, 
by our group, has been able to show that the neuroprotective efficacy by DPP-4i is mediated 
through SDF1α (209). Indeed both experimental and clinical studies have shown that SDF1α 
is an important mediator of the effect from inhibition of DPP-4 (210-213).		
 
6.4 POTENTIAL CELLULAR MECHANISMS INVOLVED IN THE 
NEUROPROTECTIVE EFFECT 
The evidence for GLP-1RA induced neuroprotection has now been confirmed in various 
studies (188-199). However, the cellular mechanisms by which these effects are mediated are 
still not clear. Potential explanations could be found in the regulation of inflammation and 
regulatory neurons, both shown to be affected by GLP-1RA treatment (Study 1 and Study 3). 
Inflammation is causing damage after stroke (46-48). Exenatide has been shown, in pre 
stroke treatment, to reduce the number of inflammatory microglia cells (189, 191, 192). Our 
post stroke treatment study did not result in reduction of pro-inflammatory cytokines (as 
measured by gene expression) but did, interestingly, show a shift in the inflammatory 
phenotype of microglia towards the so-called M2 response. This M2 phenotype has been 
linked to CNS repair (52). This shift in inflammatory response type could be one of the 
mechanisms behind the beneficial role of GLP-1RA. 
In aging animals with diabetes, we found that the number of regulatory GAD67-positive 
neurons was reduced (Study 3). This occurred in the striatum, which is the same anatomical 
structure that also demonstrated a dramatic reduction in the number of CB-positive neurons. 
This decrease in CB-positive neurons has also been confirmed by others, both in rats and 
mice (241). Striatal CB-positive neurons are linked to the regulation of dopaminergic neurons 
(242) and the striatum is involved in motor control and skills making it important in recovery 
from stroke but it is also affected in motor diseases such as Parkinson’s disease and 
Huntington’s disease (243). Studies have indeed shown a positive effect from GLP-1RA 
treatment in Parkinson’s disease and Huntington’s disease apart from the animal studies on 
stroke (75, 188, 244, 245). Our study shows that treating middle-aged diabetic GK rats with 
Ex-4 can increase the number of CB-positive neurons, thereby establishing a potential 
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mechanism for the beneficial role of GLP-1RA in these situations. It remains to be shown 
whether the changes in CB-positive neurons reflect changes in CB protein expression or in 
cellular number. In this regard, we did not observe any apoptosis at the time of sacrifice 
although cell death at earlier stages of the aging process could have occurred.  
 
6.5 ELEVATED GLP-1 AMONG STROKE PATIENTS 
The relationship between endogenous GLP-1 levels and diabetes/obesity and cardiovascular 
disease has been unclear. Some studies have found diminished GLP-1 responses to OGTT in 
diabetes with a negative association with BMI (246) while others have shown higher levels in 
diabetic patients and a positive association with BMI (247, 248). 
Several treatment studies have now shown a reduction in stroke incidence with GLP-1 
treatment (148, 149, 249), but no trial has investigated if GLP-1RA treatment influences the 
outcome of stroke (250). It has, as discussed above been shown in animals, but not in 
humans. To study the relationship between endogenous GLP-1 and stroke outcome we 
performed OGTT studies on patients that had recently had an ischemic stroke treated with 
rtPA (OGTT performed 1-3 days after the stroke). We found that the GLP-1 levels were 
higher among the stroke patients compared to healthy controls. This was true both when 
looking at fasting levels and the response during the OGTT. In the study, we unfortunately 
did not take samples at 30 minutes after glucose loading. That would probably have reflected 
the peak response optimally. Both fasting levels and the post-challenge levels were, 
nonetheless, consistently elevated among the stroke patients.  
Interestingly, we found no evidence of a difference in GLP-1 response to OGTT or in the 
fasting GLP-1 levels between the acute phase of stroke and a follow-up three months later. 
The fact that the GLP-1 levels in the acute phase and at the three-month follow-up remained 
unchanged argues against the observed difference being a consequence of the acute stroke. 
More likely it is a chronic and underlying difference; probably reflecting the levels before the 
stroke, although this is, of course, speculative. It could mean that it signals of a phenotype 
with increased stroke risk, indicative of an underlying pathophysiologic process. This is an 
area where previous studies have been conflicting. In a Swedish study on patients about to 
undergo valvular heart surgery, the levels were also found to be elevated, both the level of 
active and total GLP-1 (247). Furthermore, a Japanese study also found elevated GLP-1 
levels to be associated with risk factors for cardiovascular disease, independently from 
diabetes (248). While at the same time the opposite has been reported, with lower GLP-1 
levels in patients with established coronary disease (251). This difference is somewhat 
puzzling; it could be a consequence of progressive disease with first elevation and as a 
metabolic syndrome progress development of GLP-1 secretion dysfunction, but will have to 
be investigated further in the future.  
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The circulating endogenous levels did not show any association to the functional outcome of 
the stroke. One potential explanation for this lack of association could be that the endogenous 
GLP-1 elevation is much lower compared to a pharmacologic treatment dose. A recent article 
(2019) in Cell Reports has also demonstrated that endogenous GLP-1 and GLP-1RA exert 
their effect through different pathways (252). 
The published article originating from Study 4 only included the fasting values of GLP-1, as 
we did not have data on the GLP-1 levels 30 minutes after the glucose challenge. GLP-1 
secretion usually peaks at 30 minutes (253) and in order not to be potentially misleading only 
fasting levels were included. However, an additional analysis of the entire OGTT with all 
four time-points gave similar results with the same difference between stroke patients and 
healthy controls. This consistency in results makes it, in my opinion, unlikely that the results 
would have differed if data at 30 minutes were available.  
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7 CONCLUSION 
GLP-1RAs are neuroprotective and can be used to attenuate the impact of ischemic stroke. 
What is very important to emphasize from a clinical perspective is that neuroprotection can 
be achieved not only if the treatment is given before the onset of stroke (clinically relevant for 
T2D patients already on GLP-1-based treatment when suffering from stroke), but also if it is 
started after a stroke has already occurred (clinically relevant for virtually any stroke patient). 
Efficacy of post stroke initiated treatment is, however, time-dependent and treatment should 
be initiated as soon as possible. DPP-4 inhibition also exerts neuroprotective effects, but 
needs chronic pre-stroke treatment for efficacy. This discrepancy could be explained by the 
fact that neuroprotection induced by DPP-4 inhibition is not dependent on GLP-1. 
Furthermore, the efficacy of GLP-1RA and DPP-4i is not dependent on hyperglycemia. The 
endogenous level of GLP-1 is elevated in patients that recently suffered a stroke, and it most 
likely represents a chronic elevation; the significance of this will have to be elucidated in the 
future.  
The available data from large randomized trials have shown that GLP-1RAs reduce the 
incidence of cardiovascular events, such as stroke. Our experimental data further encourages 
the increased use of both GLP-1RA and DPP-4i in T2D with high stroke risk. Perhaps it 
should be the first add-on after metformin, to not only prevent stroke, but to also improve 
recovery in the event of a stroke.  
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8 FUTURE DIRECTIONS 
That GLP-1RA can be used to prevent cardiovascular events is known (reduced incidence), 
but there is a gap of knowledge in whether such treatment can impact the outcome of the 
event itself. Therefore studies with GLP-1RA focusing on the outcome after a stroke would 
be very interesting to see. Perhaps legacy studies after the large randomized DPP-4i trials 
could be performed.  
A limitation to the transferability of results from many experimental animal studies to patient 
care is the difference in doses used. This includes ours, where a high initial dose was used 
before the follow-up with clinical dosing. Testing of higher dose treatments in acute settings 
with neuroprotective aims in humans would be interesting. Higher doses would have a better 
chance to rapidly result in effective levels in the brain tissue and this may be important in 
time sensitive treatments such as post stroke neuroprotection.  
Studies on neuroprotection with GLP-1RA and DPP-4i have shown that it works under 
diabetic conditions, but also in subjects without diabetes. Therefore, further studies on the 
mechanisms behind the neuroprotective effect are warranted. We propose two possible 
mechanisms in this regard: the regulation of interneurons and the inflammatory phenotype 
shifting. SDF-1α is another example. These should be further studied but also other paths of 
inquiry should be pursued.  
The fact that GLP-1RA is effective both with and without the presence of concomitant 
diabetes makes a somewhat different prehospital study in suspected stroke a tempting target. 
A study including patients with all glucose values, not only hyperglycemic, has the potential 
to be easier to perform, and could possibly establish GLP-1 as a baseline treatment in stroke.  
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9 LIMITATIONS OF THE STUDIES 
First, limitations that are more general to study 1-3 will be discussed followed by more study-
specific limitations.  
9.1 EXPERIMENTAL ANIMAL STUDIES (STUDY 1-3) 
A major limitation of the studies is the fact that they are carried out in animals, reducing the 
transferability of the results. They are also all evaluated on the basis of mainly 
immunohistochemistry and to some extent inflammation markers. They lack functional data 
such as grip strength or rotarod evaluations of motor function. A weakness with 
immunohistochemical (IHC) staining is that reduction in number of staining-positive cells 
has an unclear significance. It is possible that the cells truly have gone into necrosis or 
apoptosis, but they could also be temporarily stunned with affected antigen presentation that 
with time would have reverted. When using IHC the specificity of the antibodies is important 
as well, and the dependence on this is a limitation.  
9.2 STUDY 1 
The study used high initial dosing of exenatide (5 and 50 µg/kg), albeit with the follow up 
dose being the same as clinical dose of 0.1 µg/kg twice daily. This high initial dose reduces 
the transferability. Another limitation is that the treatment was given for 1 week only. It is 
possible that a longer follow-up treatment would extend the time-window of effect after 
stroke. Moreover, how this time window transfers to humans is not clear. The time point of 
evaluation, one week after stroke, is also quite short in relation to recuperation after stroke in 
humans.  
9.3 STUDY 2 
The study shows that the treatment effect is not dependent of a GLP-1 receptor. The study 
does not, however, show through what mechanism the effect is mediated. This is a limitation 
in understanding how it works and how it could be transferred to a clinical setting. This study 
was also only performed in young animals where neuroplasticity possibly is better than in 
aged brains. A further limitation of the study, which to some extent is discussed previously, is 
that an enzyme inhibitor is not specific. DPP-4 inhibition elevates the level of GLP-1, but 
other enzyme substrates as well will be increased. This makes inference on the mechanism 
that causes the observed effect harder.  
9.4 STUDY 3 
A limitation of this study is that the exact functional role of each of the cell types tested for in 
the brain is not clearly known and established. This makes interpretation of the significance 
of the findings harder but does not in itself challenge the existence of differences between the 
normal Wistar and the diabetic GK strain. Another limitation is that the observed differences 
could be caused by animal strain differences rather than by an effect of diabetes. The GK rat 
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is, however, a derivative of the Wistar rat. It is also important to keep in mind that in relation 
to stroke, this was a pilot study performed in rats without stroke aimed to determine if T2D 
impacts interneurons and if there is potential for GLP-1RA treatment. To determine how 
interneurons/CB-positive neurons would respond to stroke and GLP-1RA would need a 
separate study.  
9.5 STUDY 4 
The GLP-1 levels were only measured after the stroke event, and estimating the levels before 
stroke is speculative. A limitation of this study is also the fact that GLP-1 was not measured 
at 30 minutes post challenge, missing the probable maximum. This was a mistake in study 
design. Inclusion of patients with diabetes, in addition to those without, would have increased 
the external validity of the study. The appropriateness of glucose loading diabetic patients in 
the acute phase of stroke could, on the other hand, be questioned. Furthermore, there was a 
difference in the age and BMI between the stroke patients and the control group. It was 
adjusted for, but one cannot rule out the risk of residual confounding.  
9.6 STUDY 5 
The main limitation is the low number of included patients. A larger sample would have been 
needed to reliably look at the glucose reduction outcome. Detecting side-effects and adverse 
events is also hard in randomized trials. The low number of treated patients means that we 
would only have a fair chance to detect adverse events expected in around 35 % according to 
the rule of three (254). The study was not designed as a neurological outcome study, but that 
would of course be of higher interest than glucose related outcomes. The short follow-up is 
another limitation; longer follow-up with repeated dosing would have been interesting. The 
study included patients in the ambulance, which in some cases turned out to have other 
diagnoses than stroke, making the cohort a less clearly defined. From a safety and feasibility 
perspective of prehospital interventions this might be less of a problem though since it 
reflects the real-life situation of prehospital care; not everything turns out to be what it 
appeared to be in the beginning.  
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Personer med typ 2 diabetes har större risk att få en stroke och när de drabbas återhämtar de 
sig sämre. Om man har högt blodsocker när man får propplösande behandling mot stroke, så 
kallad trombolys, är risken större att drabbas av en blödning som komplikation. 
Standardbehandling mot högt blodsocker är insulin. Men insulinbehandling innebär samtidigt 
en risk att blodsockret sjunker för lågt, speciellt om snabbt behandlingsresultat är målet.  
GLP-1 är ett hormon som utsöndras från tarmen när vi äter och hjälper kroppen att reglera 
blodsockret efter en måltid. GLP-1-baserade läkemedel är en läkemedelsgrupp som används 
mot typ 2 diabetes och som genom sin verkningsmekanism inte riskerar att ge för lågt 
blodsocker. GLP-1-baserade behandlingar har i studier visat sig kunna minska risken för 
stroke och annan hjärtkärlsjukdom. I tidigare djurförsök har man kunna se att det också 
minskar effekten av en stroke.  
Målet med detta forskningsprojekt har varit att närmare undersöka de hjärnskyddande 
effekterna av GLP-1-baserade läkemedel genom djurförsök och studier på människor.  
Studie 1: I denna djurexperimentella studie kunde vi se att behandling med GLP-1 
läkemedlet exenatid givet efter stroke var hjärnskyddande både i unga samt i feta/gamla djur. 
Vi såg effekt när behandlingen startades upp till 3 h efter stroke, men den försvann vid 4.5 h.  
Studie 2: I denna djurexperimentella studie använde vi ett läkemedel, linagliptin, som höjer 
de kroppsegna nivåerna av bl.a. GLP-1, men även påverkar flera andra ämnen. Vi kunde här 
se att linagliptin behöver ges före stroke för att vara skyddande. Vi kunde emellertid även se 
att linagliptin inte behöver GLP-1-receptorer för att vara hjärnskyddande.  
Studie 3: Vi undersökte om åldrandet i hjärnan hos djur med diabetes påverkar en speciell 
typ av nervceller, så kallade interneuron, annorlunda än hos djur utan diabetes. Dessa neuron 
har till uppgift att reglera övriga nervcellers aktivitet. Vi kunde se att djur med diabetes hade 
lägre nivåer av dessa neuron, men också att påverkan delvis kunde motverkas genom 
behandling med GLP-1 läkemedlet exenatid.  
Studie 4: Här undersökte vi på vilken nivå de kroppsegna nivåerna av GLP-1 ligger hos 
patienter som nyligen haft en stroke. Vi fann att de var förhöjda, både kort efter en stroke och 
var oförändrade 3 månader senare. Den kroppsegna nivån av GLP-1 i akutskedet hade ingen 
koppling till hur utfallet efter stroke blev.  
Studie 5: En ambulansstudie där patienter med högt blodsocker och misstänkt stroke lottades 
till att få standardbehandling, eller att i ambulansen få GLP-1-läkemedlet exenatid. Vi kunde 
inte se att detta påverkade blodsockret, men studien blev för liten för att kunna bedöma detta. 
Den var också ett test för att se om behandlingen medförde några problem, vilket vi inte 
kunde se.  
Sammanfattningsvis: GLP-1 baserad behandling är hjärnskyddande, men tidskritisk. 
Behandling behöver startas inom enstaka timmar för exenatid och måste ha pågått före stroke 
för linagliptin. Fynden uppmuntrar till ökad användning av dessa läkemedel vid diabetes.   
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